Pharmacology Lecture Notes

Comprehensive Review — Cardiovascular, G.I, Pulmonary, Endocrine & Related Systems

Section 1: Antiarrhythmic Drugs

1.1 The Vaughan-Williams Classification (Framework)

: Table summary: Antiarrhythmic drugs are categorized into three classes based on their mechanism and electrophysiological effects. Class IA drugs, including Quinidine, Procainamide, and Disopyramide, provide moderate sodium channel block and block potassium channels, resulting in increased QRS, QT, and PR intervals and a decreased Phase 0 rate and amplitude. Class IB drugs, such as Lidocaine, Tocainide, Mexiletine, and Phenytoin, feature weak and fast sodium channel block with a preference for ischemic or depolarized tissue, which shortens the QT interval with minimal effect on normal tissue. Class IC drugs, including Flecainide, Encainide, and Propafenone, provide strong sodium channel block with slow dissociation, leading to marked depression of Phase 0 and a marked increase in the QRS complex with little effect on repolarization.

:Table summary: Antiarrhythmic drug classes and their physiological effects. Class II drugs, such as Propranolol and Metoprolol, utilize beta-adrenergic blockade to decrease SA and AV nodal automaticity and conduction. Class III drugs, including Amiodarone and Sotalol, block potassium channels to prolong repolarization and the action potential duration, which increases the QT interval and effective refractory period without affecting Phase 0 or resting membrane potential. Class IV drugs, like Verapamil and Diltiazem, block L-type calcium channels, resulting in decreased AV nodal conduction velocity and increased AV refractoriness.

High-yield distinguishing point: Class I.A prolongs both P.R and Q.T (has quinidine-like membrane effects + K channel block); Class I.B shortens Q.T and has little effect on normal Purkinje fibers but suppresses ischemic tissue; Class I.C has the most potent Na superscript plus channel blockade (slow dissociation) and widens Q.R.S markedly without much Q.T change.

1.2 Class Ia Agents

Quinidine

• Effects on E.C.G: increased Q.R.S duration + increased Q.T interval (P.R interval is not decreased – it may increase).

- Slows conduction velocity, prolongs effective refractory period (E.R.P), reduces spontaneous ectopic pacemaker discharge.

- Has a positive chronotropic tendency due to vagolytic (anticholinergic) action — offsetting its direct depressant effect — so it does not have a negative chronotropic effect on its own; can accelerate A.V conduction if given alone in atrial flutter/fibrillation (hence combine with an A.V nodal blocker).

- Causes peripheral vasodilation in large doses (alpha-blocking property) leads to hypotension.

- Contraindicated in complete heart block (unopposed depression of conduction can be fatal).

- Cinchonism: tinnitus, headache, visual disturbance – classic dose-related toxicity of quinidine (and historically associated with cinchona alkaloids).

- Adverse effects: diarrhea, nausea/vomiting, tinnitus, headache, thrombocytopenia, and ventricular fibrillation ("quinidine syncope" from torsades due to Q.T prolongation). Hypertension is not a feature (hypotension is).

Procainamide

• Electrophysiologically resembles quinidine most closely among the options (Na⁺ channel blockade + prolonged repolarization) but lacks quinidine's alpha-blocking/anticholinergic potency.

• Associated with drug-induced lupus syndrome.

• Along with quinidine: depresses ectopic automaticity, enhances membrane responsiveness (rationale for use). Does not decrease E.R.P – it increases it.

Disopyramide

• Strong anticholinergic (antimuscarinic) side-effect profile: urinary retention, constipation, blurred vision, dry mouth.

- Also associated with lupus-like syndrome (shared class effect with procainamide).

- Negative inotrope — can precipitate heart failure; can worsen angina by this route (see 1.5).

1.3 Class Ib Agents

Lidocaine

• Shortens the effective refractory period in normal His-Purkinje tissue but prolongs E.R.P in ischemic tissue (selective action on depolarized/damaged fibers) — this is why it is useful in ischemic ventricular arrhythmias (post-M.I P.V.C's).

• Shortens the Q.T interval.

- I.V agent; first-line antiarrhythmic historically used in A.C.L.S for V.F refractory to defibrillation/epinephrine (though amiodarone is now more commonly first-line — know both).

- Toxicity: seizures (generalized), especially with propranolol co-administration — propranolol reduces hepatic blood flow / displaces or reduces clearance of lidocaine, increasing lidocaine toxicity risk (this is the classic vignette: post-M.I patient on lidocaine develops seizures after propranolol added to lidocaine toxicity).

- Class I.B agents (lidocaine, phenytoin, tocainide, mexiletine) — all four fit this class.

Phenytoin

- Class I.B: useful for digitalis-induced ventricular arrhythmias.

Tocainide / Mexiletine

- Oral congeners of lidocaine, same class I.B profile.

1.4 Class I.C Agents

- Flecainide: high affinity for and slow dissociation from fast Na ^{+} channels — the classic "use-dependent" I.C blocker.

- Propafenone: Class I.C; slows conduction by blocking Na ^{+} channels; also has weak beta-blocking activity; increases Q.R.S duration. (not Class 3 — a common distractor.)

1.5 Class 2 (Beta-Blockers) — see also Antihypertensives section for full detail

- Propranolol and other beta-blockers can worsen angina symptoms by increasing myocardial O 2 demand only if used incorrectly — actually the classic M.C.Q trap: verapamil and disopyramide (both negative inotropes/A.V blockers) can precipitate C.H.F; but the question regarding "worsening angina by increasing O 2 requirement" points to disopyramide (D only) because of its vagolytic/reflex tachycardia potential — always check the specific answer key context.

- Beta-blockers reduce ventricular response in S.V.T primarily by increasing the effective refractory period of the A.V node-shared

1.6 Class 3 Agents

Amiodarone

- Structurally contains iodine, resembles thyroxine leads to causes hyper-or hypothyroidism in 2 to 5 percent of patients.

• Pharmacokinetics: very high protein binding (99.9%), huge volume of distribution (~66 L/kg), very long half-life (~25 days) — explains delayed onset/offset of action and need for loading doses.

- Adverse effects: pulmonary fibrosis/pneumonitis, pseudocyanosis (blue-gray skin discoloration), photosensitivity, corneal microdeposits, hepatotoxicity, thyroid dysfunction. ("Parotiditis" is not a recognized amiodarone effect — distractor.)

Sotalol

- Nonselective beta-blocker that also prolongs action potential duration/E.R.P by blocking potassium (not sodium) channels — combines Class 2 plus Class 3 properties.

• Produces bradycardia, prolongs Q.T interval, increases E.R.P.

- False statement to know: sotalol does not prolong A.P.D/E.R.P "by blocking sodium channels" — it does so via potassium channel blockade.

Bretylium

Initially releases norepinephrine from nerve terminals (tran-zee-unt increase in B.P) followed by blockade of N.E reuptake/release to hypotension.

• Prolongs action potential and absolute refractory period.

1.7 Class 4 (Calcium Channel Blockers) as Antiarrhythmic

- Slow the inward calcium 2 plus current to decreased rate of phase 4 spontaneous depolarization in Purkinje/SA/A.V tissue.

- Slow A.V nodal conduction velocity, increase A.V nodal (functional) refractory period.

- Useful for rate control in atrial fibrillation.

• Hypotension is a limiting side effect.

- False statement: verapamil, diltiazem, and nifedipine do not all have equally effective antiarrhythmic activity — nifedipine (a dihydropyridine) has essentially no antiarrhythmic/A.V nodal effect; only verapamil and diltiazem (non-dihydropyridines) are useful antiarrhythmic.

- Verapamil specifically: blocks Ca superscript 2 plus channels (more so in high doses/"use-dependent" block), decreases heart rate, decreases A.V nodal conduction velocity, and decreases (not increases) A.V nodal refractoriness resistance – that is, it increases A.V nodal refractoriness. (Watch wording carefully on exams – verapamil increases A.V nodal E.R.P, decreases conduction velocity.)

1.8 Adenosine

• Ultra-short half-life: 1 to 10 seconds; metabolized by cellular uptake/deamination, not hepatic metabolism.

- Drug of choice for paroxysmal S.V.T refractory to vagal maneuvers.

• Negative chronotrope, dromotrope, and inotrope (transiently) – slows sinus rate, slows A.V conduction.

- Causes tran-zee-unt but frequent arrhythmias upon conversion (brief asystole/P.V.C's are common and expected).

- Higher doses required in patients on theophylline (adenosine receptor antagonist — competitive antagonism).

• Effects potentiated by dipyridamole (blocks adenosine reuptake).

- not given sublingually — always I.V rapid push.

• May precipitate bronchospasm (caution in asthmatics).

- Causes coronary vasodilation (not vasoconstriction – classic false-statement distractor).

- Adenosine is generally comparably or more effective than verapamil for P.S.V.T – statement claiming it is "less effective than verapamil" is False.

1.9 A.C.L.S / Emergency Points

- Epinephrine in cardiac arrest: standard dosing is 1 milligrams I.V push every 3 to 5 minutes (not weight-based 0.1 milligrams/kg, not escalating-dose regimens for adults).

- E.T tube dosing (when no I.V access): higher dose diluted in saline.

Section 2: Anticoagulants, Antiplatelets & Thrombolytics

2.1 Heparin (Unfractionated, U.F.H)

- Mechanism: binds antithrombin III, accelerating its inhibition of thrombin (factor I.I.a) and factor Xa – a poly-anionic molecule; this poly-anionic nature is essential to its mechanism (binding antithrombin and catalyzing the antithrombin-protease reaction).

- Onset: immediate (4).

• Steady-state a.P.T.T: with a bolus + constant infusion, steady state is reached after approximately 4 to 5 half-lives; heparin's half-life is roughly 1 to 1.5 hr, so a reasonable "earliest" time to check a steady-state a.P.T.T after starting an infusion is around 6 to 8 hours (exam answer: 7.5 hours, not 4 hours, since immediate levels after a bolus do not reflect steady-state infusion kinetics).

• Protamine sulfate = antidote; reverses U.F.H completely, but only partially reverses L.M.W.H (protamine does not fully neutralize the anti-Xa activity of L.M.W.H).

- Protamine itself can cause hemorrhage (paradoxically, in excess it has mild anticoagulant activity) and can cause anaphylactoid/hypersensitivity reactions.

- Heparin-Induced Thrombocytopenia (HIT): immune-mediated; antibodies form against heparin-platelet factor 4 (P.F.4) complex; this activates platelets, causing paradoxical thrombosis with a fall in platelet count (not simple bleeding risk – it's a prothrombotic state).

- Adverse effects: bleeding, thrombocytopenia (HIT), osteoporosis (long-term use), reversible alopecia. Congenital malformation/abortion is not a recognized heparin effect (unlike warfarin) — heparin does not cross the placenta, making it the preferred anticoagulant in pregnancy.

- Elimination: heparin's effect can be immediately and effectively blocked by protamine sulfate; unlike warfarin, its action does not linger for days after stopping.

2.2 Low Molecular Weight Heparin (L.M.W.H)

- Shares the basic mechanism with U.F.H (binds antithrombin) but results in more rapid/predictable inactivation of factor Xa relative to thrombin (I.I.a) – L.M.W.H preferentially inhibits Xa over I.I.a compared to U.F.H.

- Has a wider therapeutic window and more predictable dose-response than U.F.H (allows fixed/weight-based dosing without routine a.P.T.T monitoring).

• Lower incidence of HIT than U.F.H.

2.3 Direct Thrombin Inhibitors (e. g., bivalirudin, lepirudin, argatroban)

- Bind directly to the active/catalytic site of thrombin (not via antithrombin).

- Bind only to the thrombin active site – this is a bivalent or univalent direct interaction (depending on agent), contributing to high specificity/affinity.

- Do not require a.P.T.T monitoring the way U.F.H does in some formulations, but this is agent dependent (be cautious – some direct thrombin inhibitors are monitored via a.P.T.T; general classroom teaching often states an advantage is lack of dependence on antithrombin, and lack of binding to P.F.4, making them useful in HIT – since they don't bind platelet factor-4, they don't trigger the same immune reaction).

- Major drawback: poor oral bioavailability (must be given parenterally, with the exception of dabigatran which is oral).

- No specific antidote is available (unlike heparin/protamine) — bleeding is managed supportively (idarucizumab now exists for dabigatran, but this predates most exam banks).

2.4 Direct Factor Xa Inhibitors (e. g., rivaroxaban, apixaban)

- Bind directly to the active site of factor Xa, preventing conversion of prothrombin to thrombin — this occurs whether or not Xa is bound within the prothrombinase complex (unlike indirect Xa inhibition via antithrombin/fondaparinux, which cannot inhibit Xa once it's incorporated in the prothrombinase complex).

- Can be given orally and do not require routine a.P.T.T/anti-Xa monitoring.

- Bleeding risk with direct Xa inhibitors is generally not less than with indirect thrombin inhibitors — actually, real-world teaching is nuanced, but boards commonly emphasize: bleeding remains a major risk with this class, and it is not true that "bleeding is not a major risk."

- No specific antidote was historically available for older agents in this class (per this exam bank) — though andexanet alfa now exists.

2.5 Warfarin

Mechanism

- Structurally similar to vitamin K; competitively inhibits vitamin K epoxide reductase (vkorceeone) in the liver, preventing regeneration of the reduced (active) form of vitamin K.

- This prevents gamma-carboxylation (not just "synthesis") of the vitamin K-dependent clotting factors: 2, 7, 9, and X (and proteins C & S).

- Warfarin inhibits carboxylation of only newly synthesized vitamin K-dependent factors — it does not affect factors already carboxylated and circulating.

- Warfarin has no action against D.T diaphragase (an alternate vitamin K reduction pathway); this explains why high-dose vitamin K can overcome/counteract warfarin's effect via this alternate pathway.

Pharmacokinetics

• Highly (extensively) protein-bound in plasma (~99%) to albumin.

- Warfarin is not highly lipophilic with volume of distribution approximating total body water — actually it has a small volume of distribution (highly protein bound, mostly confined to plasma) — a statement claiming large Vd approximating total body water is False.

• Bioavailability depends on route/dose; well absorbed orally.

- Onset of anticoagulant action is delayed — because circulating, already-carboxylated factors (especially factor 7, with the shortest half-life approximately 6 hours, but the clinically relevant delay to full anticoagulant effect is due to the long half-life of prothrombin/factor II, approximately 60 to 72 hrs) must first be cleared before the anticoagulant effect is fully manifest. (Exam phrasing: "delay due to long half-lives of vitamin K-dependent factors in plasma" = True reasoning.)

• Extensively metabolized (hepatic C.Y.P.2.C.9) before elimination.

- Crosses the placenta leads to teratogenic and causes fetal hemorrhage leads to contraindicated in pregnancy (unlike heparin).

Monitoring & Reversal

• Prothrombin time (P.T/I.N.R) monitors warfarin therapy (reflects factors 2, 7, X — extrinsic pathway).

• Reversal: vitamin K (can take 12 to 24 hr for full effect); for rapid reversal use fresh frozen plasma/prothrombin complex concentrate.

Adverse Effects & Interactions

• Major toxicity: hemorrhage.

- Important cause of adverse drug-drug interactions (highly protein-bound, narrow therapeutic index, C.Y.P.2.C.9 substrate).

- Drugs that increase warfarin's anticoagulant effect (displace protein binding, inhibit metabolism, or reduce vitamin K availability): trimethoprim-sulfamethoxazole, N.S.A.I.D's (also displace protein binding and impair platelet function), and (per bank) note rifampin actually decreases warfarin effect via C.Y.P induction – the compilation's answer groups B & D (T.M.P-S.M.X and N.S.A.I.D's) as the interacting agents that increase effect.

2.6 Antiplatelet Agents

Aspirin

- Irreversibly acetylates cox in both the endothelium (inhibiting prostacyclin, P.G.I.2, an antiplatelet/vasodilator) and the platelet (inhibiting thromboxane A.2, a pro-aggregatory/vasoconstrictor).

- Key concept: the endothelium (nucleated cells) can synthesize new cox enzyme and recover prostacyclin production within hours, whereas platelets (anucleate) cannot synthesize new cox – so thromboxane A.2 production remains suppressed for the life of the platelet (~7 to 10 days). This differential recovery is why low-dose aspirin achieves a net antithrombotic effect.

- Low-dose aspirin is used to minimize effect on the gastric-protective prostaglandins/reduce G.I side effects while still achieving irreversible platelet inhibition.

Dipyridamole

- Inhibits phosphodiesterase and adenosine uptake, promoting vasodilation; often combined with aspirin.

- Common side effect: headache (vasodilation-related).

Cilostazol

- A phosphodiesterase (P.D.E.3) inhibitor; increases intracellular c.A.M.P to inhibits platelet activation and promotes vasodilation.

- Particularly useful for intermittent claudication / peripheral artery disease symptoms.

Phosphodiesterase Inhibitors – General

- Increase intracellular c.A.M.P levels which decreases intracellular calcium and ultimately inhibits platelet activation (this is the correct mechanistic link — P.D.E inhibition leads to increased c.A.M.P, which leads to decreased intracellular calcium 2 plus, which leads to decreased platelet activation.

2.7 Thrombolytics (Fibrinolytics)

Table summary: The mechanisms of different thrombolytic agents, ranging from non-specific indirect activators to fibrin-specific direct activators. Streptokinase acts as an indirect activator by forming a complex with plasminogen, though it is not fibrin-specific and is antigenic. Urokinase and t-PA, also known as alteplase, are direct plasminogen activators, with t-PA being more fibrin-selective but associated with bleeding and potential allergic reactions. Anistreplase is described as an anisoylated plasminogen-streptokinase activator complex.

- Thrombolytics have been shown to decrease mortality when given in the setting of acute M.I (not increase – key distractor to avoid).

2.8 Other Antithrombotic/Hemostatic Agents

- Epsilon-aminocaproic acid, tranexamic acid: antifibrinolytics (inhibit plasminogen activation) — used to stop bleeding, opposite of thrombolytics.

• Ticlopidine, clopidogrel: A.D.P-receptor (P.2.Y.12) antagonists — antiplatelet, non-cox mechanism.

Section 3: Antihyperlipidemic Drugs

3.1 Overview by Class

Lipid-lowering medications are categorized by their primary lipid effects and underlying mechanisms. Statins, such as Lovastatin and Simvastatin, primarily decrease LDL cholesterol by competitively inhibiting HMG-CoA reductase. Fibrates, including Gemfibrozil and Clofibrate, target triglycerides and VLDL via PPAR-alpha agonism. Nile acid decreases VLDL and triglycerides while increasing HDL by inhibiting hepatic VLDL secretion and suppressing adipose tissue VLDL synthesis. Bile acid resins like Cholestyramine decrease LDL by binding bile acids in the gut to upregulate liver LDL receptors. Probucol modestly decreases LDL but also decreases HDL through its antioxidant properties.

3.2 Key Mechanistic Facts (High-Yield)

• Statins are Structural Analogs of H.M.G (3-hydroxy-3-methylglutamate), a key intermediate/metabolite in cholesterol biosynthesis, and act as competitive inhibitors of H.M.G-CoA reductase (not "H.M.G-CoA synthase" — a classic distractor). H.M.G-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis.

• Inhibition of H.M.G-CoA reductase leads to depletion of intracellular cholesterol, which activates the S.R.E.B.P transcription factor, which leads to increased transcription of the L.D.L receptor gene, which leads to more hepatic L.D.L uptake from plasma, and finally results in lower serum L.D.L.

- Statins do not increase V.L.D.L production – inhibiting cholesterol synthesis does not increase V.L.D.L; this is a false/incorrect statement type on exams.

• Simvastatin's side effects: myositis/myopathy (risk of rhabdomyolysis) and G.I disturbances.

- Fibrates interact with P.P.A.R-alpha, leading to upregulation of genes related to lipid metabolism (lipoprotein lipase, apo A-I/A-I.I – this is a True statement, not a false one, on the antihyperlipidemic exam.

- Nicotinic acid (niacin) reduces V.L.D.L triglycerides (and total cholesterol/L.D.L), not "V.L.D.L triglycerides only" — it has broader effects, so a statement limiting it to "V.L.D.L only" is incorrect.

- Probucol increases H.D.L – False; probucol actually decreases H.D.L (a notable drawback of this agent) despite modestly lowering L.D.L.

• Neomycin increases L.D.L cholesterol – False; neomycin (an aminoglycoside used historically as an antihyperlipidemic) decreases cholesterol absorption.

- Lovastatin decreases H.D.L – False; statins generally modestly increase H.D.L (or are neutral), and dramatically lower L.D.L.

• Agents which indirectly enhance H.M.G-CoA reductase activity (i.e., cause compensatory upregulation because they lower intracellular cholesterol by other mechanisms) include cholestyramine (bile acid sequestration lowers hepatic cholesterol to reflex ↑ H.M.G-CoA reductase activity/L.D.L receptor expression) — this is distinct from statins, which directly inhibit the enzyme.

3.3 Adverse Effects Summary

Table summary: Notable adverse effects for several lipid-lowering drugs. Statins and Clofibrate are both associated with muscle issues, specifically myositis and rhabdomyolysis for Statins and myalgia or myositis for Clofibrate. Niacin causes cutaneous flushing, hyperglycemia, hyperuricemia, and hepatotoxicity, while Statins also list hepatotoxicity. Bile acid resins primarily cause gastrointestinal upset and interfere with the absorption of other drugs and fat-soluble vitamins.

3.4 Lipoprotein Basics

- Lipoproteins are not all of the same size/density — they range from chylomicrons (largest, least dense) to H.D.L (smallest, densest).

- Lipoproteins have a hydrophobic core (triglycerides/cholesteryl esters) and a hydrophilic (amphipathic) covering/shell (phospholipids, free cholesterol, apolipoproteins) – the reverse of a common distractor.

• V.L.D.L and L.D.L = "bad" lipoproteins (atherogenic); H.D.L = "good" lipoprotein (reverse cholesterol transport).

- L.D.L is associated with Increased (not reduced) risk of cardiovascular events.

Section 4: Antihypertensive Drugs & Diuretics

4.1 Diuretics — Site of Action Map

: Table summary: Diuretic classes and their primary sites of action in the kidney. The classes act sequentially along the nephron, beginning with Carbonic anhydrase inhibitors like Acetazolamide in the proximal convoluted tubule, followed by Osmotic diuretics like Mannitol in the proximal tubule and descending loop of Henle. Loop diuretics, including Furosemide and Bumetanide, target the thick ascending limb of the loop of Henle, while Thiazides such as Hydrochlorothiazide act on the distal convoluted tubule. The sequence concludes with Potassium-sparing diuretics, like Spironolactone and Amiloride, which work in the late distal tubule and collecting duct.

4.2 Potassium-Sparing Diuretics

Spironolactone

- Aldosterone receptor antagonist – competitively blocks aldosterone at the distal tubule/collecting duct.

• Structurally is a steroid (steroid-like nucleus).

- Adverse effects: hyperkalemia, gynecomastia, menstrual abnormalities (due to anti-androgenic/progestogenic cross-reactivity), metabolic acidosis (mild).

- Contraindicated in renal insufficiency (risk of dangerous hyperkalemia).

- Hazardous drug combinations: potassium chloride supplementation (leads to severe hyperkalemia).

Triamterene & Amiloride

- Potassium-sparing but act independently of aldosterone (direct blockade of epithelial Na superscript plus channels, E.N.a.C, in the collecting duct) — unlike spironolactone.

- Both can cause hyperkalemia, especially with potassium ion supplements.

• Shared class effect (with spironolactone): gynecomastia, hyperkalemia, menstrual abnormalities (though these are most classically associated with spironolactone, "D only" in the M.C.Q answer set).

4.3 Loop Diuretics

Furosemide

• Inhibits Na-K-2Cl cotransporter in the thick ascending loop of Henle.

• Effects: decreased renin production and aldosterone release is not typical — actually furosemide increases renin release (loss of Na sensed by macula densa to ↑ renin); increases renal blood flow and G.F.R; causes redistribution of blood flow from renal cortex to medulla.

- Can cause metabolic alkalosis (hypochloremic, hypokalemic) with chronic use.

Ethacrynic Acid

• Loop diuretic; unique among diuretics for causing ototoxicity (hearing loss) especially with I.V administration.

Shares hypokalemia, alkalosis, hyperuricemia with thiazides/other loop diuretics.

4.4 Thiazide Diuretics

- Inhibit Na-Cl cotransport in the distal convoluted tubule via inhibition of tubular electrolyte transport mechanisms (this – not alteration of G.F.R – is the main natriuretic mechanism).

- Long-term antihypertensive mechanism (after approximately 2 months): initial reduction in plasma volume gives way to a sustained reduction in peripheral vascular resistance — but per this bank's answer key, the dominant long-term mechanism cited is drug-induced saluresis/reduction in total body sodium (option reflecting decreased vascular reactivity to catecholamines secondary to Na depletion).

• Adverse effects: hypokalemia, hyperuricemia, hyperglycemia, hypercalcemia (thiazides decrease urinary calcium excretion to hypercalciuria is Wrong; correct is thiazides cause hypocalciuria/retain calcium), hyponatremia, alkalosis, hyperlipidemia.

- Thiazide-induced hypercalcemia: characterized by hypocalciuria (retained calcium 2 plus), and not typically increased serum phosphorus.

- Do not cause thrombocytopenia/agranulocytosis as a hallmark (these are rare idiosyncratic reactions, listed as the "possible" not "except" item depends on stem – check each specific stem) and do not cause hypoglycemia (thiazides cause hyperglycemia, not hypoglycemia).

- Are the most widely used first-line agents for long-term essential hypertension management (vs. osmotic, mercurial, carbonic-anhydrase-inhibitor, or xanthine diuretics).

- Hydrochlorothiazide (50 milligrams) has greater antihypertensive activity than equivalent doses of chlorothiazide (500 milligrams) – dose-potency comparison.

• Hypertension therapy with H.C.T.Z produces Greater dose-dependent B.P reduction in Black patients compared to other groups — a recognized epidemiologic pharmacology point (True statement, not the "wrong" one in Q.5.7.

4.5 Carbonic Anhydrase Inhibitors (Acetazolamide)

- Inhibits carbonic anhydrase in proximal tubule leads to decreased reabsorption of bicarbonate leads to bicarbonaturia leads to metabolic acidosis with chronic use (loss of bicarbonate ion, hydrogen ion retained... actually mechanism: causes loss of bicarbonate ions in urine).

- Effectiveness is diminished in metabolic acidosis (drug works by promoting bicarbonate loss; if body is already acidotic with low bicarbonate, less substrate/effect).

- Used for glaucoma, altitude sickness, and mild diuresis.

4.6 Osmotic Diuretics (Mannitol)

- Acts along the descending loop of Henle (and proximal tubule) by osmotically limiting water reabsorption.

4.7 Diuretic Adverse Effect Cross-Reference

Table summary: Common side effects associated with specific diuretics. Potassium-sparing diuretics, including Spironolactone, triamterene, and amiloride, cause hyperkalemia. In contrast, Thiazides and loop diuretics cause hypokalemia, hyperuricemia, and metabolic alkalosis, though acetazolamide is noted as an exception that causes acidosis. Thiazides are specifically linked to relative hypercalcemia, while loop diuretics are associated with hypocalcemia. Ototoxicity is associated with Ethacrynic acid and high-dose furosemide.

4.8 Beta-Blockers (as Antihypertensives)

- Cardioselective (beta 1 selective) agents: metoprolol, atenolol (also acebutolol, esmolol, betaxolol). Pindolol and timolol are non-selective.

- Esmolol: cardioselective, ultra-short half-life, I.V-only administration — used for acute rate control (e.g., perioperative, S.V.T).

- Sotalol: nonselective beta-blocker that also blocks K superscript plus channels (Class 3 activity), slowing heart rate and prolonging A.P.D.

• Acebutolol: cardioselective with intrinsic sympathomimetic activity (I.S.A), oral only.

- Propranolol: nonselective, has quinidine-like membrane-stabilizing (local anesthetic) effect at high doses.

- Beta-blockers with less C.N.S penetration (more hydrophilic, less lipophilic) to fewer C.N.S side effects: nadolol and atenolol (hydrophilic agents that don't cross B.B.B as readily); metoprolol/timolol are more lipophilic.

• Mechanisms of antihypertensive action of propranolol: decreased cardiac output/stroke volume, inhibition of renin release, C.N.S effects, decreased heart rate. Does not act via depletion of catecholamines (that's reserpine's mechanism) – this is the correct Except answer.

- Beta-blockers may lower B.P by: altered baroreceptor sensitivity, altered sympathetic tone in the C.N.S, altered peripheral adrenergic neuron function — not by increased prostacyclin biosynthesis (that is unrelated / a distractor).

- Propranolol adverse effects: bradycardia, bronchoconstriction (nonselective beta 2 blockade – dangerous in asthma), reduced myocardial contractility, prevention of epinephrine-induced vasodilation (unopposed alpha effect can worsen peripheral vasospasm), and masking of hypoglycemia symptoms/hyperglycemia is a Known concern but propranolol is more associated with masking hypoglycemia than directly causing hyperglycemia – check specific stem wording: per Q.1.8.5.8, hyperglycemia is listed as the exception (not typically caused by propranolol; more a concern with thiazides).

- Propranolol is detrimental (contraindicated or used cautiously) in bronchial asthma (bronchoconstriction), but is actually beneficial in conditions like hyperthyroidism (controls adrenergic symptoms), atrial fibrillation (rate control), and hypertension.

- Contraindications to propranolol: bronchial asthma, sinus bradycardia, 2nd/3rd degree heart block, decompensated C.H.F. not contraindicated in migraine prophylaxis — in fact propranolol is used prophylactically for migraines.

4.8 Sympatholytics (Central & Peripheral)

Clonidine

- Central alpha 2-agonist leads to reduces sympathetic outflow from the vasomotor center in the medulla.

- Abrupt discontinuation to withdrawal/rebound hypertensive crisis (sympathetic surge) — a serious, well-known adverse reaction. Important perioperative teaching point: continuing clonidine through surgery avoids this risk; stopping abruptly (even with concurrent thiazide) risks rebound hypertension, not hypotension.

- Fluid/salt retention can occur with chronic central sympatholytic use (part of "pseudotolerance"/resistance mechanism), similar to methyldopa.

Methyldopa ( alpha -Methyldopa)

- Acts as a false neurotransmitter: converted to alpha-methylnorepinephrine which is a potent central alpha 2 -agonist (converted centrally in the C.N.S, not simply "in the periphery"—a common false-statement trap: "exerts its effect through conversion in neurons in the periphery to alpha-methylnorepinephrine" is False because the key site of action is central).

- Preferred antihypertensive in pregnancy (long track record of safety) - True, a well-established use.

- Adverse effects: positive direct Coombs' test, hemolytic anemia, drug-induced fever, hepatotoxicity. Diarrhea is not a typical side effect – methyldopa more classically causes sedation and dry mouth; nephrotic syndrome is also not a typical association (correct Except answers).

- Causes sedation, decreased libido/drive, depression – classic vignette: hypertensive patient on methyldopa with new depressive symptoms/loss of "drive."

- Contraindicated/used cautiously in patients with mental depression / history of depression and liver disease (hepatotoxicity).

- Causes salt and water retention (contributing to "pseudotolerance"), similarly to clonidine.

Reserpine

- Depletes catecholamine (norepinephrine) stores in nerve terminals (blocks vesicular monoamine transporter, vmat.

- Adverse effects: bradycardia, postural hypotension, diarrhea (unopposed parasympathetic/G.I activity), nasal stuffiness, and importantly depression (can be severe, even precipitate suicidality) — historically important teaching point.

- Most contraindicated in patients with mental depression / history of depression (of the listed options in the bank, vs renal, coronary, liver disease, or asthma).

- Does not cause reflex tachycardia (unlike direct vasodilators) because it works via catecholamine depletion, not direct arteriolar dilation.

Guanethidine / Guanadrel

- Guanadrel is pharmacologically similar to guanethidine (both block release of norepinephrine from postganglionic sympathetic neurons / block the neuronal uptake and storage of N.E – "adrenergic neuron blockers").

- Adverse effects: orthostatic hypotension, enhanced sensitivity to sympathomimetics (denervation supersensitivity), diarrhea, retrograde ejaculation, sedation, dry mouth – but does not typically cause bradycardia as a defining "except" feature per Q.1.3.2.0.2 (constipation is the "except" answer there – guanethidine more classically causes diarrhea, not constipation).

- Reduced tissue norepinephrine levels result from chronic treatment with guanethidine and reserpine (both deplete/block N.E) – alpha-methyl-tyrosine (a tyrosine hydroxylase inhibitor, blocks N.E synthesis) is a different, less commonly used mechanism but also reduces N.E; per this bank's key, guanethidine + reserpine is the marked correct pairing.

- Effectiveness of guanethidine (and other adrenergic-neuron blockers dependent on neuronal N.E uptake, like clonidine to a lesser extent) is diminished by concomitant tricyclic antidepressants T.C.A's block neuronal reuptake, preventing guanethidine's uptake into the nerve terminal where it must act) – clonidine's central effect can also be antagonized by T.C.A's.

4.9 Direct Vasodilators

Hydralazine

- Direct arteriolar (not venous) smooth muscle relaxant.

- Causes reflex tachycardia (baroreceptor-mediated sympathetic activation, since arterial pressure drops), fluid retention, and a lupus-like syndrome (dose and acetylator-status dependent).

- Also associated with hypertrichosis is a minoxidil feature, not hydralazine – hydralazine's own notable "except" adverse effect list includes reflex tachycardia, lupus syndrome, sodium/water retention (with orthostatic hypotension being less prominent since it's arterial-selective).

- Most contraindicated in coronary insufficiency (reflex tachycardia increases myocardial O.2 demand, can precipitate angina/ischemia).

• Hydralazine does not relax venous smooth muscle (arteriolar-selective vasodilator) — True/correct statement.

Minoxidil

- Opens K plus (A.T.P-sensitive) channels in vascular smooth muscle leads to hyperpolarization leads to decreased calcium 2 plus entry leads to vasodilation (increases potassium conductance – this is a True, not wrong, statement).

- Causes reflex tachycardia and fluid retention (managed by adding a beta-blocker and/or diuretic).

• Reserved for severe/refractory hypertension, particularly useful in renal failure patients (since it doesn't rely on renal excretion for its antihypertensive benefit and works well when other agents fail).

- Notable side effect: hypertrichosis — actually used therapeutically (topical) for androgenic alopecia — this is an advantage/use, so calling it a "wrong" statement would be incorrect; it's a True beneficial side-application.

- Minoxidil is effective for long-term/sustained use in appropriate refractory hypertension cases — a statement claiming it's "not effective for sustained treatment, reserved for short-term only" would be the Wrong (false) statement, since minoxidil actually is used long-term in refractory cases.

Diazoxide

- Structurally related to thiazide diuretics (a benzothiadiazine derivative) but has no diuretic effect — instead a potent direct arteriolar vasodilator (opens K-A.T.P channels, similar to minoxidil), used historically for hypertensive emergencies via rapid I.V bolus.

• Causes reflex tachycardia and fluid/salt retention (like hydralazine).

• Additional use: inhibits insulin release from pancreatic beta cells to used to treat hypoglycemia (e.g., insulinoma).

Sodium Nitroprusside

- Direct arterial and venous vasodilator (balanced effect on both preload and afterload) — donates no.

- Onset of action: seconds (extremely rapid, requires continuous I.V infusion with careful titration/monitoring).

• Metabolized to cyanide, then thiocyanate – prolonged use or renal impairment can lead to thiocyanate toxicity.

- Must be given as a continuous I.V infusion, not rapid I.V push — rapid bolus would cause severe, uncontrolled hypotension (this is the False/incorrect statement to identify: "must be given by rapid I.V push injection" is Wrong).

Trimethaphan

- Ganglionic blocker — blocks nicotinic receptors at autonomic ganglia, reducing sympathetic vascular tone; used (historically) for hypertensive emergencies and controlled hypotension during surgery.

4.10 ace Inhibitors (Captopril, etcetera)

• Mechanism: block conversion of Angiotensin 1 to Angiotensin 2, thereby preventing A.T.1 receptor stimulation; also decrease aldosterone secretion (leading to reduction in preload/volume); and prevent bradykinin degradation (ace = kininase I.I, which contributes to vasodilation, but bradykinin accumulation is also responsible for the characteristic dry cough and angioedema – not vasoconstriction. (A statement claiming A.C.E.I's "prevent bradykinin degradation leading to vasoconstriction" is Incorrect – bradykinin causes vasodilation, not vasoconstriction.)

• Reduce arterial tone (afterload reduction).

- Risk factors for captopril toxicity: bilateral renal artery stenosis (can precipitate acute renal failure by removing angiotensin I.I-mediated efferent arteriolar constriction that maintains G.F.R) and congestive heart failure (patients often volume-depleted/renin-dependent, higher risk of first-dose hypotension and renal effects).

- Adverse effects: dysgeusia (taste disturbance), fetal toxicity/potential (contraindicated in pregnancy – fetopathy), angioedema, cough, hyperkalemia, acute renal failure (in stenotic kidneys), rash, proteinuria.

4.11 Miscellaneous Antihypertensive Points

- Chlorothiazide is associated with hyperuricemia and can precipitate acute gout, as can high-dose salicylates; spironolactone does not typically induce hyperuricemia (K-sparing agents are relatively uricosuric-neutral or even protective compared to thiazides/loops).

- The antihypertensive agent most likely to increase cardiac output: chlorothiazide (via reduced afterload/vasodilation over time relative to other options in that stem) — direct arterial vasodilators like hydralazine typically increase heart rate/C-O acutely via reflex tachycardia too, so context of the specific stem matters.

- Maximum diuretic antihypertensive effectiveness is typically achieved only after approximately 5 to 6 weeks of consistent daily dosing (chronic adaptation of vascular tone), not immediately.

- The critical/dominant long-term mechanism of diuretic-induced B.P reduction is reduction of total body sodium content (leading to decreased vascular smooth muscle reactivity/peripheral resistance over time) rather than persistent plasma volume contraction alone.

Section 5: Gastrointestinal Pharmacology

5.1 Laxatives — Classification & Mechanism

Table summary: Laxative types and their mechanisms of action. Bulk-forming agents like methylcellulose and bran work by adding bulk and water to stool to mechanically stimulate peristalsis. Saline osmotic options, such as sodium sulfate and magnesium sulfate, increase intraluminal water retention to increase volume and stimulate peristalsis. Stimulants, including castor oil and cascara, directly increase intestinal motor activity by irritating the mucosa or enteric nerves. Emollient and lubricant agents, such as mineral oil and docusate sodium, soften the stool to ease passage without increasing peristalsis. Finally, non-absorbable osmotic sugars like lactulose are fermented by colonic bacteria, creating an osmotic effect and lowering colonic pH.

Table summary: Alkalinizing agents, specifically Sodium bicarbonate, function through a mechanism that can lead to systemic alkalosis if the substance is absorbed.

- Saline cathartics are not readily absorbed from the G.I tract (that's the point – they stay in the lumen to draw water in); they are contraindicated/used cautiously in renal failure (risk of accumulation of absorbed magnesium/phosphate to toxicity), and act by increasing intestinal volume, stimulating peristaltic action – not by lowering surface tension (that's a surfactant/emollient laxative mechanism, for example, docusate).

- Docusate sodium promotes defecation without increasing peristalsis (it works by lowering surface tension/stool softening).

- Sodium bicarbonate — most likely of the listed options to cause systemic alkalosis if significant amounts are absorbed.

- General laxative adverse effects: electrolyte disturbances (hyponatremia typically, not hypernatremia – check specific stem), dehydration, spastic colitis with stimulant laxatives, and G.I obstruction risk with bulk-forming agents (especially if inadequate fluid intake) – all are valid concerns ("all of the above" is often correct for this general question type).

- Appropriate uses of laxatives: preventing straining at stool in cardiovascular patients, bulk agents for diverticular disease, and treatment of drug overdose (whole bowel irrigation-type indications) — but not to induce daily bowel movements in otherwise normal, healthy individuals (this is inappropriate/unnecessary use).

- Lactulose in hepatic encephalopathy: works via (1) reduced fecal pH from bacterial breakdown products to reduces ammonia absorption via non-ionic diffusion trapping N.H.3 converted to N.H.4 which is poorly absorbed), (2) the decreased fecal pH increases bacterial assimilation of ammonia for their own protein synthesis, and (3) induces an osmotic diarrhea, diminishing fecal stasis and reducing nitrogenous substrate contact time with colonic mucosa. All three mechanisms are correct/valid (comprehensive answer = all).

- Laxatives aid in portal-systemic encephalopathy by: increasing stool pH is actually decreasing – but net teaching point per this bank is that laxatives help by decreasing protein contact time with G.I mucosa, altering colonic flora, and reducing ammoniagenic substrate – comprehensive/multiple mechanisms are correct.

5.2 Acid-Peptic Disease Agents

Antacids

- Non-systemic (minimally absorbed) antacids: aluminum hydroxide and calcium carbonate are relatively non-systemic; sodium bicarbonate is systemically absorbed (can cause systemic alkalosis) — so a question asking which are "non-systemic" should exclude sodium bicarbonate; but per this bank's stated answer key (#19, answer 4 "all of the above"), context of specific phrasing should be checked carefully — general teaching: sodium bicarbonate is the systemic outlier.

• Aluminum hydroxide binds/chelates and interferes with G.I absorption of tetracyclines (also fluoroquinolones) via chelation – clinically important drug interaction.

- Concomitant calcium/magnesium antacids with tetracyclines: decreases the antibacterial action of the tetracycline (via chelation, reducing absorption/bioavailability).

• Antacids should be dose-adjusted or avoided based on electrolyte content (sodium, phosphate, magnesium) in patients with renal insufficiency, C.H.F, and ascites (fluid/electrolyte-sensitive states) — general caution across all three.

• Pharmacologic effects of antacids: increase gastric pH, reversible inactivation of pepsin at pH greater than 6 (pepsin requires an acidic environment for activity), can increase or decrease gastric motor activity depending on the specific antacid (magnesium salts tend to have a laxative/prokinetic effect, aluminum salts tend to be constipating), and decrease lower esophageal sphincter pressure is generally false — actually antacids and alginate combinations are often used because they do not significantly worsen les tone; check specific stem, but the classically correct combination in this bank is (A, B, C) – increase pH, inactivate pepsin, alter motility.

H.2-Receptor Antagonists (Cimetidine, Ranitidine)

• Attenuate the gastric acid secretory response by: (1) preventing binding of histamine released from E.C.L cells (by gastrin or vagal stimulation) to the H.2 receptor, (2) direct stimulation of the parietal cell by gastrin or acetylcholine has a diminished effect on acid secretion in the presence of H.2-receptor blockade (because H.2 blockade removes a key "potentiating" signal that amplifies gastrin/A.C.H-mediated acid secretion – the potentiation phenomenon), and (3) inhibits nocturnal acid secretion most effectively of the three phases (basal, nocturnal is largely histamine-driven).

- Cimetidine is a potent S.I.P.4.5.0 inhibitor — reduces hepatic clearance of many drugs: theophylline, phenytoin, warfarin, quinidine are all affected. Digoxin clearance is renal, not significantly hepatic, so cimetidine does not meaningfully reduce digoxin clearance — this is the correct Except answer.

- Cimetidine is uniquely associated (compared to other H.2 blockers) with anti-androgenic effects: gynecomastia, muscle pain (myalgia), and constipation – this is a well-known distinguishing adverse effect profile.

• Ranitidine and other newer H.2 blockers have far less anti-androgenic activity than cimetidine.

Proton Pump Inhibitors (Omeprazole, etcetera)

• Mechanism: irreversibly inhibit the H superscript plus/K superscript plus A.T.P.ase ("proton pump") on the parietal cell — this is direct inhibition of the final common pathway of acid secretion, distinguishing P.P.I's from H.2.R.A's (which act indirectly, by blocking only the histamine limb of stimulation).

- P.P.I's decrease acid secretion through Direct action on H^+/K^+ A.T.P.ase, while H.2.R.A's indirectly inhibit H^+/K^+ A.T.P.ase (by blocking one of the receptors — histamine — that stimulates the pump, rather than blocking the pump itself). This distinction is the key exam concept.

- P.P.I's cause decreased intragastric acidity which can actually contribute to (not impede) eradication of H. pylori when used as part of combination regimens (raising gastric pH improves the activity/stability of certain antibiotics like clarithromycin and amoxicillin, and creates an environment less favorable to H. pylori) — a statement that P.P.I's "decrease intragastric acidity whilst contributing to the eradication of H. pylori" is a True, well-recognized synergy (used correctly here as the non-Wrong option).

Misoprostol

- A P.G.E.1 analog; inhibits gastric acid secretion by directly stimulating P.G.E.1 receptors on parietal cells (not via H+/K+A.T.P.ase blockade — a different, prostaglandin-receptor-mediated mechanism), and also promotes mucus/bicarbonate secretion (cytoprotection).

- Especially useful for N.S.A.I.D-induced ulcers (prophylaxis, since N.S.A.I.D's work by inhibiting prostaglandin synthesis — misoprostol replaces the deficient P.G.E.1).

- Contraindicated / used with caution in women of childbearing age — it is an abortifacient/uterotonic (causes uterine contractions) — must avoid in pregnancy.

- It does not selectively bind to "ulcer craters" in the gut mucosa in a targeted fashion — this is a False distractor description (that mechanism describes sucralfate, not misoprostol).

Sucralfate

- A sucrose-aluminum sulfate complex; requires an acidic pH in the stomach to polymerize/activate and adhere to the ulcer crater (forms a protective barrier over the ulcer bed) — hence should not be co-administered with agents that raise gastric pH (antacids, H.2.R.A's, P.P.I's) too closely in timing.

- Most common side effect: constipation (due to the aluminum component).

- Does not reduce gastric acid secretion by antagonizing gastrin, does not enhance Na-K A.T.P.ase, does not antagonize acetylcholine, and does not increase gastric motility – its mechanism is purely local/physical (mucosal-adherent barrier), so all pharmacologic-receptor-based mechanism options are false; correct answer is the side-effect option (constipation).

Pirenzepine

- A parasympatholytic (antimuscarinic) agent that is relatively selective for gastric M.1 receptors — acts as an antispasmodic (used historically to reduce gastric acid secretion with fewer systemic anticholinergic effects than atropine).

5.3 Prokinetic Agents

Metoclopramide

- Mechanism: central dopamine (D.2) receptor Antagonist (not agonist – a common distractor) in the chemoreceptor trigger zone (antiemetic effect), and peripherally enhances acetylcholine release/sensitizes muscarinic receptors in the upper G.I tract to increases lower esophageal sphincter pressure (not decreases – another distractor), increases gastric emptying, and increases small bowel motility. Does not significantly increase colonic motility.

- Adverse effects: dystonic/extrapyramidal reactions (due to central D.2 blockade), sedation, and hyperprolactinemia/galactorrhea.

- Used adjunctively in esophagitis/gerd management (along with elevation of the head of bed, avoidance of ethanol/tobacco, small frequent meals).

• Bethanechol (a direct muscarinic agonist) is also used historically to increase les tone in gerd, distinguishing it from metoclopramide's dopaminergic mechanism.

5.4 5-H.T.3 Antagonists & Antiemetics (from pharm sections)

• Ondansetron: a 5-H.T.3 receptor antagonist used as an antiemetic.

- Antihistamines H.1 blockers) used as antiemetics/anti-motion sickness agents act centrally in the C.N.S by blocking muscarinic and histamine receptors, with additional vestibular apparatus effects —

Section 6: Pulmonary Pharmacology (Asthma & C.O.P.D

6.1 Theophylline (Methylxanthine)

Mechanism (proposed, multiple)

• Inhibits phosphodiesterase (P.D.E) leads to increased intracellular cyclic A.M.P leads to bronchodilation.

• Blockade of adenosine receptors (adenosine causes bronchoconstriction; theophylline is a competitive antagonist).

• Translocation of intracellular calcium.

(Xanthine oxidase inhibition is not a proposed bronchodilator mechanism of theophylline — a distractor; this is actually the mechanism of allopurinol, unrelated to bronchodilation.)

Pharmacokinetics & Drug Interactions

• Metabolized hepatically S.I.P.1.A.2, 3.A.4 – narrow therapeutic index, requires monitoring.

• Clearance Decreased (levels increased, risk of toxicity) by: cimetidine, ciprofloxacin, and other S.I.P.1.A.2/3.A.4 inhibitors — ranitidine has much less effect than cimetidine on hepatic enzymes (so pairing cimetidine + ciprofloxacin, not ranitidine, as the answer for "decreases clearance").

• Clearance also reduced by: phenobarbital is actually an Inducer (increases clearance) – check carefully; per this bank, theophylline clearance may be reduced by phenobarbital, warfarin, tobacco smoking, phenytoin, ciprofloxacin is listed as "5. ciprofloxacin" as the standalone best/most robust answer in one stem, while phenytoin and phenobarbital are actually enzyme inducers that Increase clearance (lower theophylline levels) – smoking also increases clearance (induces S.I.P.1.A.2. Be attentive to each specific question's framing; general important rule: enzyme inducers (phenobarbital, phenytoin, tobacco/cigarette smoking, rifampin) to increased clearance/lower levels; enzyme inhibitors (cimetidine, ciprofloxacin, erythromycin) to decreased clearance/higher levels/toxicity risk.

- Factors important in selecting a theophylline maintenance dose: smoking history, concomitant medications, presence of C.H.F or cor pulmonale, hepatic failure — not significantly affected by renal insufficiency (theophylline is hepatically cleared, so renal function is the least relevant factor of the choices).

Toxicity

• Manifestations: tremors, seizures, tachyarrhythmias, vomiting/nausea – hyperkalemia is not a feature; theophylline toxicity classically causes hypokalemia (via beta-adrenergic-like intracellular K ^{+} shift) – so hyperkalemia is the correct Except answer.

- Management of oral overdose: enhance clearance via oral pulse-dose activated charcoal (repeated doses enhance elimination via "Glidolysis"); not by inducing emesis, lavage of nasogastric contents alone, forced diuresis, or cimetidine administration (cimetidine would worsen toxicity by inhibiting metabolism!).

- Chronic aminophylline abuse can lead to tolerance is a nuanced statement — but the more classically tested "wrong" answer relates to administration technique: theophylline (I.V aminophylline) should be administered slowly over 30 minutes with pulse monitored (rapid I.V push is dangerous — can cause fatal arrhythmias).

6.2 Beta-2 Adrenergic Agonists

- Selective beta 2 agonists (bronchodilators with less cardiac/beta 1 stimulation): terbutaline, albuterol, metaproterenol, pirbuterol, salmeterol.

- Isoproterenol is non-selective ( beta 1 plus beta 2 ) — it is the odd one out among the beta-agonist list and would have the least selective/most cardiac-stimulating profile; conversely, when comparing relative beta 2

(bronchodilation) effect at normal doses, norepinephrine has essentially no beta 2 activity (predominantly alpha and beta 1) — making it the agent with the least bronchodilator effect among sympathomimetics.

• Salmeterol: a beta 2 -selective long-acting agonist, used for asthma prophylaxis (controller), not for acute symptomatic relief (too slow onset for rescue use).

- Adverse effects of beta-2 agonists: nervousness, headache, tachycardia, tremulousness – lethargy is not typical (they are stimulatory, causing more of the opposite – restlessness/tremor).

- β2 agonists and methylxanthines: both cause immediate and marked bronchorelaxation and are used as relievers, and both cause side effects referable to the cardiovascular and C.N.S systems — True statements; tolerance to their effects should be carefully avoided/monitored (with chronic use, receptor downregulation can occur) — all are considered valid/true concerning statements ("all of the above" answer type in relevant stems).

6.3 Anticholinergic Bronchodilators

- Ipratropium bromide: works through cholinergic (muscarinic) receptor antagonism – blocks vagally-mediated bronchoconstriction; the aerosolized form is a mainstay of contemporary asthma/C.O.P.D management (especially C.O.P.D.

- Contrast with isoetharine (a direct-acting sympathomimetic beta agonist, not anticholinergic).

6.4 Mast Cell Stabilizers

- Cromolyn sodium: best described as an inhibitor of mast cell degranulation (prevents release of histamine and other mediators) — it is not a bronchodilator, anticholinergic, beta agonist, or glucocorticoid; used purely for prophylaxis, has no role in acute bronchospasm relief.

- Nedocromil: similar mast-cell-stabilizing mechanism; contrary to a dismissive "insignificant benefit" statement, nedocromil does provide meaningful benefit via mast cell membrane stabilization — a statement claiming its benefit "is insignificant" would be the Incorrect statement on an exam about bronchial asthma management.

6.5 Leukotriene Modifiers

- Leukotriene pathway inhibitors (e.g., montelukast, zafirlukast, zileuton) — contrary to a dismissive statement, these agents do provide substantial benefit in asthma management; a statement saying they are "usually not of substantial benefit" is the Incorrect/false statement to identify.

6.6 Adenosine Antagonism & Bronchodilation

- Enprophylline, a potent bronchodilator methylxanthine kon-jeh-ner, notably blocks adenosine receptors much less than theophylline does (it is relatively "adenosine-sparing") yet retains potent bronchodilator activity – highlighting that adenosine receptor blockade is not the sole/essential mechanism for methylxanthine bronchodilation. A statement that "enprophylline blocks adenosine receptor" as its defining characteristic is generally considered the False statement (since its distinguishing feature is the opposite – minimal adenosine antagonism relative to theophylline).

- Methylxanthines (as a class) cause tremors and insomnia as adverse effects (True), and generally do not cause constriction of blood vessels (they are more associated with mild vasodilation in some beds, or are neutral) — "cause constriction of most blood vessels" is the False statement in that context. They can induce diuresis (mild, via renal tubular effects and increased G.F.R) — True.

6.7 Loop Diuretics & Theophylline – Shared Renal Mechanism (Cross-topic)

Theophylline, ethacrynic acid, and furosemide all interfere with active renal tubular reabsorption of sodium and increase urine volume; contrary to any suggestion otherwise, they are effective in the treatment of congestive heart failure (loop diuretics are

Section 7: Cardiac Glycosides (Digitalis), Inotropes & Vasodilators

7.1 Digitalis (Digoxin/Digitoxin) — Mechanism

- Direct mechanism: inhibits the sodium potassium A.T.P.ase pump on the cardiac myocyte membrane leads to increased intracellular sodium, which leads to reduced sodium calcium exchanger activity, which leads to increased intracellular calcium available to the contractile machinery, resulting in a positive inotropic effect.

- Digitalis phosphorylates the Na-K-A.T.P.ase reversibly — binding/inhibition is at the enzyme's phosphorylated intermediate state, and this inhibition is reversible, not irreversible.

- The rate of binding of digitalis to Na⁺/K⁺A.T.P.ase is Increased in hypokalemia (low extracellular K⁺ favors digitalis binding to the pump, since K⁺ and digitalis compete for the same/an overlapping binding site) — this is why hypokalemia potentiates digitalis toxicity.

- Digitalis competes with potassium for binding to the Na ^{+} /K ^{+} A.T.P.ase — this competitive relationship explains why hypokalemia increases toxicity risk and why potassium administration can help manage certain forms of digitalis toxicity.

- Structurally, the cardiac glycosides resemble steroids (steroid nucleus) – not catecholamines, salicylates, nitrofurantoin, or phenothiazines.

- The lactone ring is responsible for the pharmacologic activity of digitalis (interacts with the receptor/enzyme); the sugar moiety (glycone) is responsible for solubility/pharmacokinetic properties, not the direct activity – so a statement claiming "the sugar moiety is responsible for its activity" is Incorrect (sugar = solubility; lactone ring = activity).

- Digitalis does not have direct effects on the heart to increase A.V nodal delay in a direct pharmacologic-receptor sense that's independent of its indirect vagal-potentiating action – but the classically tested "Incorrect statement" items usually target: digitalis directly increasing A.V conduction, or lacking any effect on intracellular calcium – review each specific stem carefully, as the bank tests multiple negative/positive framings of the same core facts.

7.2 Digitalis – Electrophysiologic & Hemodynamic Effects

• Mechanisms by which digitalis slows heart rate / ventricular response (particularly in atrial fibrillation):

1. Direct action on the A.V node to slow conduction.

2. Indirect (vagomimetic) effect: enhanced vagal tone acting on the A.V node.

3. Enhanced parasympathetic outflow from the C.N.S via an indirect mechanism (central vagal stimulation).

4. Diminished sympathetic tone, which is pathologically elevated (as a compensatory mechanism) in heart failure — digitalis, by improving contractility/cardiac output, reduces the compensatory sympathetic drive.

5. Digitalis does not work by "enhanced responsiveness of the SA/A.V node to norepinephrine" – this is the incorrect (Except) mechanism (digitalis's rate-slowing effect is fundamentally vagally mediated and via reduced sympathetic tone, not enhanced catecholamine responsiveness).

- E.C.G effects of digitalis (classic "digitalis effect"): borderline P.R interval prolongation (A.V nodal slowing), sagging/scooped S.T segment depression, and a Shortened Q.T interval (due to shortened Purkinje/ventricular E.R.P — hallmark distinguishing feature from most other cardioactive drugs, which prolong Q.T). This combination (prolonged P.R + scooped S.T + short Q.T) = classic "digitalis effect" pattern.

- Digitalis effect on refractory periods: shortens the effective refractory period of Purkinje fibers/atrial muscle (contributing to its pro-arrhythmic potential at toxic doses — enhanced automaticity + shortened E.R.P = re-entry substrate) while prolonging the functional refractory period of the A.V node (this is the therapeutic rate-control mechanism in afib. A statement claiming digitalis "shortens" the A.V nodal functional refractory period is the Incorrect (Except) statement — it's the opposite: A.V node E.R.P is prolonged, Purkinje/atrial E.R.P is shortened.

- Digitalis primarily controls atrial fibrillation ventricular rate by slowing conduction through the A.V node (not by slowing atrial rate itself, and not by an atropine-like/vagolytic effect — that would be the opposite of its actual vagomimetic action).

- In therapeutic doses, digitalis: slows the ventricular rate in atrial fibrillation (the primary clinical rationale for use in afib — it does not reliably slow the atrial rate in sinus tachycardia, does not enhance A.V conduction (it slows it), and does not decrease ventricular automaticity (in fact toxic digitalis increases ventricular automaticity/ectopy).

7.3 Digitalis in Normal versus Failing Hearts

In normal (non-failing) hearts: digitalis increases cardiac output?

no — actually in the normal heart digitalis primarily increases myocardial contractility and myocardial O.2 consumption without a corresponding increase in useful cardiac output (since the normal heart isn't preload/contractility-limited) — it can even cause vasoconstriction in the normal heart secondary to enhanced sympathetic outflow and blockade of vascular smooth muscle Na/K⁺A.T.P.ase, and it increases total peripheral resistance (not reduces it) in normal individuals.

- In the failing (dilated) myocardium, digitalis produces a net Decrease (or no change) in myocardial oxygen consumption — because the improvement in contractility/emptying reduces ventricular wall tension/size (Laplace's law: reduced radius reduces wall stress) enough to offset the direct inotropic O.2 cost. This is a key concept: digitalis raises M.V.O.2 in the normal heart but does not raise (or may even lower) M.V.O.2 in the failing dilated heart.

- Digitalis has not shown proven value in prophylaxis for diastolic dysfunction (its benefit is in systolic dysfunction/reduced ejection fraction).

• In acute M.I: digitalis is generally not recommended in uncomplicated M.I, and patients with acute M.I are considered more (not less) sensitive to the arrhythmogenic effects of digitalis toxicity (ischemic myocardium is more prone to digitalis-induced arrhythmias). In normal hearts, digitalis does increase contractility and myocardial O.2 consumption (True), and in failing hearts it decreases or leaves unchanged myocardial O.2 consumption (True) — so the correct combined answer is (A, C) true, (B, D) false.

7.4 Digitalis Toxicity

- Cardiac manifestations: P.V.C's (most common), various degrees of A.V block (2nd/3rd degree), A.V junctional escape beats, and paradoxically atrial tachycardia with A.V block is the "classic" digitalis toxicity arrhythmia – atrial fibrillation with a Rapid ventricular response is an Uncommon manifestation of digitalis toxicity (digitalis toxicity more typically causes bradyarhythmias/blocks or ectopy with slow-to-normal rates, not rapid afib – that's the correct "uncommon" answer).

• Treatment of digitalis-toxic P.V.C's: lidocaine, phenytoin, and digoxin-specific immune Fab (Digibind) are all appropriate; quinidine is not appropriate – quinidine actually increases serum digoxin levels (displaces digoxin from tissue binding sites, reduces renal clearance) and worsens digitalis toxicity, so it is contraindicated in this setting.

- Digitalis-induced emesis: mediated via stimulation of the chemoreceptor trigger zone (C.T.Z) in the area postrema (a central mechanism, not direct G.I irritation alone) – occurs with both oral and parenteral administration (not exclusive to oral), and is of real clinical importance (an early sign of toxicity to monitor for) – the C.T.Z stimulation is the correct mechanistic answer, not a G.I Na/K-A.T.P.ase-linked mechanism.

• Digitalis toxicity is potentiated by: hypokalemia (competitive binding, as above), hypomagnesemia, hypercalcemia, renal insufficiency (for digoxin, which is renally cleared), hypothyroidism, and quinidine/verapamil/amiodarone co-administration (pharmacokinetic interactions that raise digoxin levels).

7.5 Digoxin versus Digitoxin – Pharmacokinetic Comparison

Table summary: Digitoxin is characterized by a much longer half-life of about 7 days compared to Digoxin's 36 to 48 hours, reflecting their different clearance pathways. Digitoxin is extensively metabolized hepatically and is less affected by renal disease, whereas Digoxin is primarily eliminated renally and requires dose adjustments for renal function. Additionally, Digitoxin has significantly higher protein binding at 90 to 97 percent compared to roughly 25 percent for Digoxin, and it offers more complete and consistent oral absorption and more extensive enterohepatic circulation.

• Compared to digitoxin, digoxin is: less highly protein-bound, has less extensive enterohepatic circulation, has a Shorter elimination half-life, and is less completely absorbed orally – and is not more extensively hepatically cleared (digoxin is renally cleared; this is the key distinguishing, correct "True" statement – digoxin is less completely absorbed orally, matching option 4 in the source bank).

- Digitoxin half-life: approximately 7 days (long) — allows for more stable, less fluctuating steady-state levels but a much longer washout period if toxicity occurs; its clearance is largely independent of renal function (advantage in renal failure patients), and it has a much Lower incidence of toxicity in renal disease compared to digoxin (since digitoxin isn't renally cleared) — a statement claiming digitoxin "has a much higher incidence of toxicity in renal disease" would be the Incorrect statement to identify.

- Digitoxin gastrointestinal absorption is generally complete and reliable (not "incomplete and highly variable" — that statement would be False/incorrect, since digitoxin's lipophilicity actually gives it very good, consistent oral bioavailability, unlike digoxin which can be more variable).

• Maintenance dose of digoxin is primarily dependent upon renal function (since digoxin is cleared renally, unlike digitoxin).

7.6 Other Positive Inotropes

Dobutamine

- A synthetic catecholamine, predominantly beta 1 -agonist (positive inotrope with less chronotropic/vasopressor effect than isoproterenol/dopamine at typical doses).

• Does not inhibit troponin I – it works via classic beta 1 -adrenergic receptor/c.A.M.P signaling, not via a bipyridine-type phosphodiesterase-inhibitor mechanism.

Amrinone / Milrinone (Bipyridines)

• Phosphodiesterase-3 (P.D.E.3) inhibitors — increase intracellular c.A.M.P in cardiac and vascular smooth muscle to positive inotropy + vasodilation ("inodilators").

- They do not work by "inhibiting troponin I" (a commonly tested distractor – no clinically used inotrope works via direct troponin inhibition).

- Correctly matched drug-mechanism pair: digoxin – inhibits Na superscript plus/K superscript plus A.T.P.ase pump (this is the one True pairing among common distractor options like "dobutamine–inhibits troponin I," "amrinone–inhibits troponin I," "dopamine–inhibits troponin I," which are all false).

Dopamine

- Dose-dependent receptor effects: low dose to dopaminergic (D.1) receptors, promoting renal vasodilation and direct diuretic- : promoting effect on the kidney; intermediate dose leads to beta 1 (inotropy); high dose leads to alpha 1 (vasoconstriction/pressor effect).

- Of the sympathomimetics listed, dopamine is the one that promotes diuresis via a direct renal effect (distinguishing it from isoproterenol, dobutamine, norepinephrine, epinephrine).

Thiocyanate Toxicity Risk

- Among amrinone, nitroglycerin, milrinone, and nitroprusside, only nitroprusside (D only) carries the risk of thiocyanate/cyanide toxicity (via its nitroprusside arrow cyanide arrow thiocyanate metabolic pathway).

7.7 Nitrates & Nitroglycerin

• Mechanism: increases intracellular c.G.M.P (via no donation leading to activation of guanylate cyclase) leading to vascular smooth muscle relaxation.

• Sublingual nitroglycerin is standard route for acute anginal attacks.

- Tolerance Does develop to the effects of organic nitrates with continuous/frequent use — this is a well-known clinical phenomenon requiring nitrate-free intervals; a statement claiming "tolerance does not develop" is the False statement to identify.

- Major beneficial effect in classical (exertional) angina is due to nitrates' propensity to dilate veins more than arteries — reducing preload (venous return) predominantly, thereby reducing ventricular wall tension and myocardial O.2 demand, rather than primarily increasing coronary blood flow via arterial dilation (though some coronary/collateral dilation also occurs).

- Contraindicated in cerebral hemorrhage (risk of further increasing intracranial pressure/bleeding via vasodilation).

- Reflex tachycardia after nitroglycerin is best explained by reflex sympathetic discharge secondary to the fall in systemic blood pressure (baroreceptor-mediated reflex), not a direct chronotropic effect on the myocardium, and not by nitroglycerin directly releasing norepinephrine from nerve terminals.

- Reduction in intramycardial wall tension is the primary mechanism by which nitroglycerin reduces myocardial oxygen demand (via reduced ventricular volume/preload — Laplace's law), more so than a primary reduction in heart rate or blood pressure per say, though these contribute too.

• Actions of nitrates in angina: cause peripheral venous pooling to decreased preload, decrease in ventricular size, decrease systolic blood pressure, and cause a reflex Increase in heart rate (not decrease) – but a statement claiming nitrates cause an increase in ejection fraction as a primary direct mechanistic action would be the incorrect/exception answer in certain framings (nitrates primarily reduce preload/wall stress; E.F changes are a secondary consequence, not the primary listed pharmacologic action in that specific Except stem – review exact wording).

7.8 Orthostatic Hypotension — Drug Causes

- Among sympathomimetics/antihypertensives, reserpine (catecholamine-depleting agent) is most likely to cause orthostatic hypotension – compared to direct-acting pressors (phenylephrine, metaraminol) which support B.P, or amyl nitrite (primarily used diagnostically/for cyanide poisoning, causing hypotension acutely but not the "most likely" chronic orthostatic-hypotension-causing agent in this comparison set).

Section 8: N.S.A.I.D's, Gout & Anti-Inflammatory / Rheumatologic Agents

8.1 Prostaglandin Synthesis & nsaid Basics

- cox-1: constitutive enzyme, present in most tissues (stomach, kidney, platelets) — maintains "housekeeping" prostaglandin functions (gastric mucosal protection, renal blood flow, platelet thromboxane A.2 production).

- cox-2: largely inducible (at sites of inflammation), though it does have some constitutive expression (e.g., kidney, brain) — a statement that "cox-1 is constitutive while cox-2 is inducible" is broadly True (the classic correct teaching point), whereas a statement claiming they "catalyze different pathways in prostanoid biosynthesis" is False (both cox-1 and cox-2 catalyze the same basic reaction — conversion of arachidonic acid to P.G.G.2/P.G.H.2 — they differ in tissue distribution/regulation, not in the chemical pathway catalyzed).

- Aspirin inhibits both cox-1 and cox-2 (irreversibly) — a statement limiting aspirin's inhibition to only cox-1 (and not cox-2) is False.

- Ibuprofen inhibits both cox-1 and cox-2 (reversible, nonselective) — a statement claiming ibuprofen inhibits cox-2 but not cox-1 is False.

- Acetaminophen is a weak/preferential C.N.S-cox inhibitor, with minimal peripheral anti-inflammatory activity – but it is generally understood to have some cox inhibitory activity at the central level (the classic exam distractor claiming "cox-2 is inhibited by acetaminophen while cox-1 is not" should be evaluated against the specific stem's framing).

- Objective of selective cox-2 inhibition: to lower the risk of G.I toxicity (since cox-1-mediated gastric mucosal protection is preserved) while retaining anti-inflammatory efficacy – the primary rationale is G.I safety, not necessarily improved anti-inflammatory efficacy (efficacy is comparable to nonselective N.S.A.I.D's) or reduced nephrotoxicity (renal risk is not reduced with cox-2 selectivity – renal cox-2 is constitutively important) or reduced duration of R.A treatment.

8.2 nsaid Adverse Effects & Special Populations

- Traditional (non-selective) N.S.A.I.D's: have shown negative effects on the pathophysiology of asthma (can precipitate bronchospasm/“aspirin-exacerbated respiratory disease” in sensitive individuals), and negative (not positive) effects on the pathophysiology of cerebral and myocardial infarction (can increase cardiovascular thrombotic risk, particularly with cox-2 selective and some non-selective agents) — a claim that N.S.A.I.D's have "established positive effects on pathophysiology of cerebral/myocardial infarction" is False. N.S.A.I.D's also do not have a clearly positive effect on colon cancer pathophysiology in the sense implied by exam distractors, though epidemiologic data suggests chemopreventive potential in some contexts – treat cautiously per exam key (marked false/not established as therapeutic).

- N.S.A.I.D's are nephrotoxic and should be used cautiously (not "cannot be used") in the elderly — a statement that "N.S.A.I.D's are nephrotoxic and cannot be used in the elderly" being labeled True would depend on exact stem wording, but the general correct teaching is that they carry real nephrotoxic risk requiring caution, especially in the elderly and volume-depleted patients.

• Antipyretic action of N.S.A.I.D's is primarily mediated via inhibition of both cox-1 and cox-2 in the hypothalamus (nonselective mechanism for fever reduction), not exclusively one isoform.

- Combining a cox-1-selective agent with a cox-2-selective agent to "achieve better therapeutic result with reduced adverse effects" is not an accepted/valid strategy – this is the False statement (this combination doesn't confer additive benefit while minimizing toxicity in accepted practice – it would simply add the toxicities of both).

8.3 Gout & Hyperuricemia Management

Pathophysiology

• Gout is characterized by recurrent, usually monoarticular arthritis.

- Inflammation is activated by phagocytosis of urate crystals by polymorphonuclear leukocytes (neutrophils) — the central pathophysiologic event in acute gouty attacks.

• Gout can arise from overproduction or decreased excretion of uric acid, and can also arise secondary to chemotherapy (tumor lysis syndrome-related hyperuricemia) — all are valid causes.

Colchicine

- Mechanism: binds to tubulin, preventing/decreasing microtubule polymerization, which interferes with cell division (arrests mitosis, classically at metaphase – though note it is not primarily classified as an "antineoplastic agent working on the M phase" as a distractor might suggest — its major clinical use is anti-inflammatory in gout, via inhibition of leukotriene B.4 (L.T.B.4) and interference with neutrophil/granulocyte migration and degranulation, decreasing leukocyte chemotaxis into the joint.

- Due to high tissue uptake, only about 10% of a single dose is eliminated in the first 24 hours – the elimination of colchicine from the body may continue for days after the last dose (prolonged tissue retention).

- Effective in gout because it suppresses leukocyte activation (chemotaxis, phagocytosis, degranulation) — not primarily via a uric-acid-lowering mechanism (colchicine does not significantly lower serum uric acid levels; it treats the inflammatory response to crystals).

- Adverse effects: G.I toxicity is most common (nausea, vomiting, diarrhea) — an early symptom patients should be counseled about.

- Sudden reduction of serum uric acid (e.g., from starting allopurinol without colchicine prophylaxis) can precipitate an acute gouty attack (mobilization of urate from tissue deposits) — a well-known clinical pearl, hence colchicine or nsaid prophylaxis is often co-prescribed when initiating urate-lowering therapy.

Allopurinol

- Mechanism: a purine analog that is itself a substrate/inhibitor — is a prodrug converted by xanthine oxidase to alloxanthine (oxypurinol), which is a potent inhibitor of xanthine oxidase — thereby decreasing purine metabolism/conversion of hypoxanthine and xanthine to uric acid, lowering serum uric acid.

- Directly inhibits xanthine oxidase as well (both allopurinol and its metabolite oxypurinol contribute to enzyme inhibition).

- Best/primary application is in chronic management (prevention of recurrent attacks/tophi), not in the acute attack setting — allopurinol should generally not be started during an acute gouty flare (can prolong/worsen the attack) — a statement claiming its "best application is in management of acute attacks" is the Incorrect statement to identify.

- Effective even when the underlying defect is decreased excretion of uric acid (works regardless of whether the cause is overproduction or underexcretion, since it reduces production of uric acid overall) — True statement.

- Does not act as a "neuroprotectant by preventing free radical formation that triggers programmed cell death" – this is an unrelated, False distractor (allopurinol's relevant mechanism is xanthine oxidase inhibition for uric acid reduction, period).

- Large doses of vitamin C can increase the risk of renal calculus formation in some contexts (via increased oxalate) — a nuanced but recognized point in gout/urate management discussions.

Febuxostat

- A non-purine xanthine oxidase inhibitor that works by non-competitively blocking the active site of xanthine oxidase (mechanistically distinct from allopurinol's purine-analog structure).

- Useful in adults with gout who have inadequate response to or intolerance of allopurinol.

- Does not "color the stool black" like bismuth salicylate — this is a False distractor (that black-stool effect is specific to bismuth compounds, unrelated to febuxostat).

- Is not classified as a "uric acid synthesis inhibitor employed in the acute exacerbation of gout" — like allopurinol, it's used for chronic management, not acute flares — this framing is the Incorrect/false statement.

Probenecid & Sulfinpyrazone (Uricosuric Agents)

- Probenecid: works by competitively inhibiting the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentration — a uricosuric agent (increases renal excretion, opposite mechanism from allopurinol which decreases production).

- Probenecid is effective in gout because reabsorption of uric acid predominates over secretion in the kidneys — by blocking reabsorption, net excretion increases.

- Sulfinpyrazone: possesses cox-inhibitory (antiplatelet) effects but Lacks the anti-inflammatory and analgesic properties typical of standard N.S.A.I.D's (unlike its structural relative phenylbutazone) – used historically for chronic gout management (uricosuric), but is not used in the long-term management of acute attacks per say – clarify per specific stem, generally it is used chronically for hyperuricemia, but is not useful for treating an acute attack itself (lacks anti-inflammatory action).

• Weak organic acids like thiazides Compete with urate at the proximal convoluted tubule – this is why thiazide diuretics can precipitate hyperuricemia/gout (they compete for the same secretory/reabsorptive transporters, net effect reducing urate excretion).

8.4 Glucocorticoids

- Primary goal of glucocorticoid treatment in rheumatoid arthritis: suppression of inflammation and improvement in functional capacity — not eradication of symptoms, reversal of the degenerative disease process, or "development of a sense of well-being" as the primary intended goal (though mood elevation can be a side effect) — and definitely not "prevention/suppression of the hypothalamic-pituitary-adrenal axis" (that's an unwanted side effect of glucocorticoid therapy, not a treatment goal).

• Mechanism of glucocorticoid anti-inflammatory action: they act by preventing the synthesis and release of leukotrienes – mechanistically, glucocorticoids induce lipocortin/annexin-1, which inhibits phospholipase A.2, thereby blocking the release of arachidonic acid and downstream production of both prostaglandins and leukotrienes (a broader block than N.S.A.I.D's, which only inhibit cox/prostaglandins) – this is why glucocorticoids are more broadly anti-inflammatory than N.S.A.I.D's.

• Glucocorticoids are always used as controllers (not relievers) in the prophylactic control of bronchial asthma — appropriate role framing.

- Osteoporosis with chronic glucocorticoid use is due to: inhibition of calcium absorption (from the gut) and bone formation – not an increase in calcium excretion as the primary mechanism (though secondary hypercalciuria can occur due to reduced intestinal absorption triggering compensatory changes) – the key correct answer centers on impaired osteoblast function/bone formation and reduced intestinal calcium absorption.

- Mechanism of glucocorticoid immunosuppression (as used for prednisolone, for example) includes: inhibition of lymphocyte proliferation, down-regulation of cytokine gene expression (interference with transcription regulation), reduced T-cell activation via I.L-1 and I.L-6 pathways, and poor chemotaxis with reduced lysosomal enzyme release by neutrophils and monocytes – all are valid mechanisms (comprehensive, "all of the above"-type correct answer across these listed effects).

- Dexamethasone: has a much longer biological half-life than cortisol (a statement claiming it has "a half-life equivalent to that of cortisol" is False); produces minimal-to-no salt retention even in therapeutic (high) doses (unlike cortisol/hydrocortisone, dexamethasone has negligible mineralocorticoid activity — a claim that it "produces salt retention in therapeutic doses" is False); it does not possess most of the undesirable side effects of cortisol — it's specifically favored because of its higher glucocorticoid-to-mineralocorticoid selectivity ratio (a claim that it possesses "most of the undesirable side effects of cortisol" is a poorly worded/likely False framing in this context — dexamethasone's key selling point is reduced mineralocorticoid-related side effects, though glucocorticoid-related side effects like osteoporosis, hyperglycemia, and H.P.A suppression remain a concern with prolonged use); its anti-inflammatory potency is much Greater than (not equivalent to) cortisol on a milligram basis (a claim that "anti-inflammatory potency is equivalent to that of cortisol" is False — dexamethasone is roughly 25-30x more potent than cortisol by weight).

- Dexamethasone is not adequate as replacement therapy in an adrenalectomized patient (because it lacks mineralocorticoid activity — patients would need fludrocortisone or hydrocortisone which has combined activity) — a claim that "dexamethasone is adequate replacement therapy in an adrenalectomized patient" is the False/incorrect statement.

8.5 Osteoporosis-Steroid Mechanism (Detail)

• Glucocorticoid-induced osteoporosis is due to their ability to: inhibit calcium absorption and bone formation (the correct, highlighted mechanism) — options like "increase excretion of calcium," "stimulate the H.P.A axis," "decrease production of prostaglandins," and "suppress arachidonic acid synthesis" are distractors describing other, unrelated glucocorticoid actions, not the osteoporosis mechanism specifically.

8.6 Rheumatoid Arthritis – Targeted (Biologic/dmard) Therapy

• Pharmacological targets in R.A management typically include: tumor necrosis factor (T.N.F), Janus kinase (J.A.K), and B-lymphocytes (rituximab targets C.D.20+ B cells) – Phospholipase A.2 is not a standard pharmacologic target in current R.A biologic therapy (this is the correct "does not include" answer).

Methotrexate

- A disease-modifying antirheumatic drug (dmard) — inhibits dihydrofolate reductase (at higher/oncologic doses) but in R.A works at low doses largely through anti-inflammatory mechanisms (adenosine-mediated).

- Has an advantage of increased benefit-to-risk ratio compared to many other D.M.A.R.D's, contributing to its status as first-line/anchor dmard in R.A.

- Methotrexate and gold (an older dmard, now rarely used) have established effects on progression of tissue/joint damage — True, distinguishing true D.M.A.R.D's from purely symptomatic agents.

- Disease-modifying agents generally show their clinical effects only after long-term administration (delayed onset of action, weeks to months) — True.

- A statement claiming D.M.A.R.D's "generally have little effect on the progression of bone & cartilage destruction" is False – this is precisely the defining feature that distinguishes true D.M.A.R.D's from purely symptomatic agents (N.S.A.I.D's/glucocorticoids control symptoms but don't reliably halt structural progression the way D.M.A.R.D's do).

Leflunomide

- Undergoes enterohepatic circulation (contributing to a very long half-life).

- Cholestyramine significantly reduces its plasma levels (interrupts enterohepatic recirculation) – used clinically for rapid "washout" of leflunomide if needed (e.g., before pregnancy or in case of serious toxicity).

- Does not typically require folic acid pretreatment before initiating treatment (unlike methotrexate, which does) – a claim that "usual treatment requires administration of folic acid before treatment" would be the False statement for leflunomide specifically.

- Has no clear teratogenic potential per this stem's framing is listed as an option, but leflunomide is actually known to be teratogenic in practice/real-world prescribing – treat per the specific exam key context (the bank lists "has no teratogenic potential" as one of several claims evaluated for truth/falsity – clinically leflunomide is considered teratogenic, so this claim would generally be considered False in standard pharmacology teaching, though the exact answer key here should be checked against the source).

Calcineurin Inhibitors (Cyclosporine, Tacrolimus)

- Exert immunosuppressive effects by inhibiting production of interleukin-2 (I.L-2), not by "inducing" interleukin production — a statement claiming they act "by inducing interleukin productions" is False (correct mechanism: calcineurin inhibition blocks N.F.A.T-mediated transcription of I.L-2, suppressing T-cell activation/proliferation).

- Available in both oral and parenteral preparations for clinical use — a claim that "only parenteral preparations are available for clinical use" is False.

- Tacrolimus is approximately 10 to 100 times more potent than cyclosporine on a molar basis.

- It is generally easier to monitor cyclosporine blood levels than tacrolimus (more standardized assays/experience historically) — though modern practice monitors both closely; per this bank, a claim reversing this ("easier to monitor tacrolimus than cyclosporine") would be False.

- hyperglycemia/diabetogenicity (and nephrotoxicity, neurotoxicity) — a claim that tacrolimus's notable side effect is hypokalemia is generally considered the False statement (tacrolimus is more associated with hyperkalemia, not hypokalemia, along with nephrotoxicity/hyperglycemia).

Thalidomide

- Increases production of I.L-10 (an anti-inflammatory cytokine) as part of its immunomodulatory mechanism — relevant in conditions like erythema nodosum leprosum and certain hematologic malignancies (multiple myeloma).

Immunopharmacology — General Agent Classes

- Monoclonal antibodies are used as immunosuppressants and anti-inflammatory agents in modern rheumatology/transplant medicine.

• Immunostimulants employed in immunopharmacology include: interferons, interleukin, vaccines, and colony-stimulating factors — all are valid examples of immune-system-boosting biologic therapies.

8.7 Hypersensitivity Reaction Classification (Gell & Coombs) – Drug Reactions

Table summary: Type I hypersensitivity is characterized by an IgE-mediated mechanism involving mast cell and basophil degranulation, which leads to immediate reactions such as anaphylaxis and urticaria.

Table summary: Characteristics of Type II, Type III, and Type IV hypersensitivity reactions. Type II reactions involve IgG or IgM antibody binding to drug-modified cell-surface antigens, resulting in cytotoxic effects like penicillin-induced hemolytic anemia, with symptoms typically resolving days after drug withdrawal. Type III reactions are characterized by immune complex deposition, often involving IgG, which can lead to serum sickness; these occur less frequently than Type I reactions and are mediated by immune complexes rather than being cell-mediated. Type IV reactions are defined as cell-mediated or delayed-type hypersensitivity, featuring three subtypes based on T-cell subpopulations and causing tissue damage through indirect toxic effects such as cytokine release and cytotoxic T-cell action.

Table summary: Key characteristics of Type IV hypersensitivity, noting that damage is driven by the release or production of cytokines rather than their inhibition. Additionally, this type of reaction is classically delayed, typically occurring more than 36 hours following exposure, peaking between 48 and 72 hours.

- Proposed mechanisms for auto-immune drug reactions/disorders include: exposure of self-reactive B-lymphocytes to antigens previously sequestered from the immune system, inappropriate exposure to Class 1 and Class 2 M.H.C complexes, and molecular mimicry (pathogens with antigenic determinants that do not share identical/similar epitopes with normal host tissues would actually not trigger molecular mimicry – molecular mimicry specifically requires antigenic similarity between pathogen and host; a description stating pathogens' antigens "do not share identical or similar epitopes with host tissues" describes the opposite of molecular mimicry, and would be the False/incorrect characterization of that specific mechanism).

Section 9: Endocrine Pharmacology

9.1 General Hormone Action Principles

- Peptide/protein hormone receptors (e.g., for A.C.T.H, T.S.H, insulin) are typically located on the outer surface of the target cell membrane — True.

- Hormone action is not always mediated by a second messenger – many hormones (especially steroid and thyroid hormones) act via intracellular/nuclear receptors that directly regulate gene transcription, bypassing classical second-messenger cascades – a claim that "hormone action is always mediated by a second messenger" is the Untrue/False statement.

• Examples of second messengers: c.A.M.P, I.P.3, and D.A.G – all correct examples.

- Steroid hormones have intracellular (not extracellular) receptors – True, consistent with their lipophilic nature allowing membrane diffusion.

- Because steroid hormones are hydrophobic, they are carried in circulation bound to specific transport proteins (e.g., cortisol-binding globulin, sex hormone-binding globulin) — True.

- Most hormones produce effects by first forming a hormone receptor complex – True (nearly universal principle).

- This receptor complex can open/close ion channels or activate G-proteins, depending on receptor type — but importantly, most hormones that open ion channels do so Indirectly through G-protein activation (not all receptor types are ligand-gated ion channels directly) — review specific stem wording carefully, as this concept is nuanced across different receptor superfamilies.

• lons whose altered transmembrane movement leads to post-receptor effects include: K⁺, Na⁺, Cl⁻, and Ca squared⁺ — all are relevant to hormone-mediated signal transduction (comprehensive/inclusive correct answer).

9.2 Posterior Pituitary Hormones

Oxytocin

• Physiological roles: uterine contraction and parturition (labor induction/augmentation), and milk ejection ("let-down") reflex during lactation — not "milk production" per say (that is prolactin's role) and not "uterine rupture" as a normal physiologic role (that would be a pathologic complication of excessive/uncontrolled use, not a physiologic role) – so a description including "uterine rupture" as a normal physiologic role is False/incorrect framing.

- Prolactin (an anterior pituitary hormone), not oxytocin, stimulates milk production/synthesis by the mammary glands – oxytocin only causes milk ejection (via myoepithelial cell contraction), not synthesis – a statement claiming "oxytocin stimulates the secretion and synthesis of milk" conflates the two hormones and is False; the correct statement is that prolactin stimulates the synthesis of milk by the mammary glands.

- Ergonovine is considered among the most active agents for control of postpartum hemorrhage (uterotonic, ergot alkaloid).

Vasopressin (A.D.H)

• Mechanism of antidiuretic action: increases the permeability of the membrane of the renal collecting duct to water, acting via V.2 receptors (which stimulate insertion of aquaporin-2 water channels), enhancing water (and secondarily sodium) reabsorption in the collecting ducts.

- V.1 receptors mediate vasoconstriction (vascular smooth muscle); V.2 receptors mediate the antidiuretic (renal collecting duct) effect — "stimulation of V.1 and V.2 receptors in the tubules" as a description of the antidiuretic mechanism is only partly accurate/an oversimplification (V.1 is not the tubular water-permeability receptor) — the single Best description remains "increased permeability of the renal collecting duct membrane to water."

- Lack of vasopressin results in Excessive production of dilute urine (diabetes insipidus) — True, a correct statement about A.D.H physiology.

- A.D.H does not inhibit diuresis in the kidney as its mechanistic description (it promotes water reabsorption, which is the basis for reduced urine output, but describing the mechanism simply as "inhibition of diuresis" is imprecise/incomplete compared to the specific aquaporin/permeability mechanism) – best answer remains the specific "increased collecting duct water permeability" mechanism.

Pituitary Hormones – General

- Prolactin stimulates milk synthesis by the mammary glands – the single Correct statement among distractors (oxytocin does not stimulate synthesis; vasopressin lack causes Excessive, not lack of, urine production; oxytocin and vasopressin secretion is regulated by hormones released by, not simply "regulated by," the hypothalamus – the hypothalamus synthesizes oxytocin/vasopressin, which are then stored and released from the posterior pituitary, a nuance often tested).

9.3 Thyroid Pharmacology

Iodides (Pharmacologic/High-Dose Use)

- High-dose iodide (e.g., Lugol's solution) has immediate, short-term effects on thyroid hormone release/synthesis (Wolff-Chaikoff effect) — used pre-operatively to reduce thyroid vascularity — a claim that iodides "inhibit all aspects of thyroid hormone metabolism" is an overreach/False (they primarily block hormone release and synthesis acutely, not every aspect of peripheral metabolism), and a claim that iodides "have no place in the management of thyroid storm" is False — iodides are used (after antithyroid drugs) in thyroid storm management.

- Iodides also have side effects referable to the immunologic system (hypersensitivity-type reactions, "iodism").

- Iodism: refers to hypersensitivity reactions and manifestations resembling serum sickness; does not refer to "the rebound hyperthyroidism occurring 14 days after iodide administration" (that describes the Jod-Basedow phenomenon or escape from Wolff-Chaikoff, a distinct concept) – this mismatch is the Wrong statement to identify regarding iodism.

Radioactive Iodine ^{131}I

- Major untoward effect: hypothyroidism (from destruction of thyroid tissue) — this occurs in a dose-dependent manner and its effects are not immediate — takes weeks to months for the full ablative/hypothyroid effect to manifest; a claim that it "has immediate dose-dependent effects" is False.

- Selectively destroys thyroid tissue with little collateral damage to surrounding structures — True (due to selective iodine uptake by thyroid follicular cells).

• Does interfere with thyroid hormone metabolism testing/uptake studies for a period – a claim that"131 doesn't interfere with thyroid hormone metabolism" is False in most contexts tested.

Thioamides (Propylthiouracil, Methimazole)

- Mechanism: inhibit thyroid peroxidase, blocking organization of iodide and coupling of iodotyrosines – this does not inhibit "all aspects" of thyroid hormone metabolism (peripheral effects, existing hormone stores are unaffected acutely).

- Propylthiouracil (P.T.U) is the thioamide of choice during pregnancy/lactation (traditionally preferred in the first trimester specifically and sometimes in lactation due to lower transplacental/breast-milk transfer relative to methimazole, though current practice has nuances – this is the classically tested "correct" answer).

- Agranulocytosis with thioamides is classically described as a reversible, dose-dependent effect in some teaching frameworks, though clinically it is often considered an idiosyncratic reaction — per this bank's framing, it is characterized as the commonest serious side effect requiring monitoring, and described in this context as "reversible, dose-dependent" per the specific answer key given.

• Regarding antithyroid drug agranulocytosis in general: thiourelylenes (thioamides) cause dose-dependent, reversible agranulocytosis necessitating regular white cell count monitoring during therapy — per the specific stem's answer key (marked True/comprehensive "all of the above").

General Antithyroid Therapy Points

- The pharmacologic effects of iodides (like other antithyroid agents) are noticed only after a latent period – True (delayed onset due to existing hormone stores needing depletion).

- I"doesn't interfere with thyroid hormone metabolism" was noted above as generally False per most standard teaching (uptake studies are affected).

9.4 Hypothalamic-Pituitary-Adrenal (H.P.A) Axis & Adrenal Disorders

Congenital Adrenal Hyperplasia (C.A.H)

• Diagnosis supported by measuring cortisol precursors and plasma dehydroepiandrosterone sulfate (D.H.E.A-S) – elevated due to enzymatic block (commonly 21-hydroxylase deficiency) shunting steroid synthesis toward androgen precursors.

- C.A.H can be effectively treated by: restoring negative feedback for A.C.T.H release (via glucocorticoid replacement, which suppresses excess A.C.T.H-driven adrenal androgen overproduction), or by administering an androgen antagonist, or by administering metyrapone to decrease cortisol synthesis — Wait: metyrapone actually blocks cortisol synthesis and would be used diagnostically (to test H.P.A axis reserve, that is, the metyrapone stimulation test) or in Cushing's, not as C.A.H treatment (C.A.H treatment requires glucocorticoid Replacement, not further cortisol synthesis blockade) — so a statement listing "administering metyrapone to decrease cortisol synthesis" as an effective C.A.H treatment strategy would be False/incorrect in the C.A.H context specifically.

Cushing's Syndrome – Ketoconazole

- Ketoconazole in the management of Cushing's disease: its Most appropriate characterization is that it has an action on the adrenal cortex that may be associated with liver dysfunction – ketoconazole is a well-known hepatotoxic agent (inhibits multiple P.4.5.0 steroidogenic enzymes, including those in the adrenal cortex, useful off-label for cortisol-excess states, but carries significant hepatotoxicity risk requiring monitoring).

- Ketoconazole does not have "a single major action confined to the adrenal cortex" (it inhibits multiple S.I.P.4.5.0 enzymes broadly, including gonadal steroidogenesis, hence also causing gynecomastia/reduced libido as side effects) – this "single confined action" framing is False.

- It does not provide reliable long-term treatment for Cushing's disease as a definitive/preferred therapy (used more as bridging/adjunctive therapy) – and its adrenal cortical enzyme inhibition is not irreversible (it's a reversible, dose-dependent enzyme inhibitor) – claims to the contrary are False.

- It does not preferentially block cortisol synthesis "as opposed to testosterone production" — in fact it notably also blocks testosterone/gonadal steroidogenesis (a clinically relevant side effect, gynecomastia/impotence), so it is not selective for the adrenal axis alone.

Osteoporosis Due to Glucocorticoids (Adrenal-related – cross-reference Section 8.4)

• Covered above: inhibition of calcium absorption and bone formation.

Management of Adrenal Insufficiency / Cushing's – Surgical & Alternate-Day Therapy

- Removing the adrenal gland surgically (adrenalectomy) and alternate-day glucocorticoid therapy are both recognized strategies in the broader management/prevention-of-side-effects context in relevant clinical scenarios (alternate-day dosing specifically helps minimize H.P.A axis suppression while maintaining therapeutic benefit).

9.5 Reproductive/Gonadal Pharmacology

5-alpha Reductase Deficiency

- A male who lacks functional 5-alpha reductase (cannot convert testosterone to dihydrotestosterone, D.H.T) would be expected to have: elevated serum levels of testosterone (since conversion to D.H.T, the primary means of testosterone's peripheral degradation/action in certain tissues, is blocked, testosterone itself accumulates) — along with ambiguous external genitalia at birth (D.H.T-dependent) but normal internal male anatomy (testosterone/A.M.H-dependent) and normal-to-elevated pubertal virilization at puberty (testosterone surge partially compensates). The single best/highlighted correct finding: elevated serum testosterone levels.

Antiestrogens (Clomiphene)

- Clomiphene is usually administered early in the follicular phase of the menstrual cycle (typically days 3 to 5) to induce ovulation.

- Poses an increased risk of multiple births/multiple gestation (due to multi-follicular development).

- Major mechanism: modulation of feedback inhibition by estrogen at the hypothalamic-pituitary level, resulting in an increase in gonadotropin (F.S.H/L.H) secretion – this is the correct, True mechanistic description.

• Clomiphene does not cause "enlargement of the ovaries and increased secretion of oestrogen" as its primary mechanism of therapeutic action per this bank's framing of the Untrue statement — while ovarian enlargement (multi-follicular development, sometimes ovarian hyperstimulation) can occur as a side effect, describing this as its core mechanism of action (rather than the antiestrogenic feedback-based mechanism) is the intended False/untrue statement in that specific stem.

9.6 Ergot Alkaloids & 5-H.T Receptor Agents

- Ergot alkaloids exert agonist, partial agonist, and antagonist actions at alpha-adrenoceptors (complex, mixed pharmacology depending on the specific ergot derivative and tissue) — the correct comprehensive description; they do not act primarily at beta-adrenoceptors, H.1, or muscarinic receptors as their defining action, and while some ergots do have serotonergic actions (relevant to migraine treatment and vasospasm), the core defining receptor pharmacology taught is the complex alpha-adrenergic agonist/partial agonist/antagonist profile.

- Ergonovine = most active ergot alkaloid for control of postpartum hemorrhage (potent uterotonic).

- Ergot alkaloids are partial agonists or antagonists at adrenergic, dopaminergic, and serotonergic receptors — a broad, multi-receptor pharmacology, correctly capturing their complexity (this comprehensive framing is the True statement about their receptor pharmacology).

Triptans (5-H.T.1.B/1.D Agonists)

- Unlike ergot alkaloids, triptans do not produce tachycardia, hypotension, or vasoconstriction in the same broad/non-selective manner — they are much more selective and potent for the specific 5-H.T.1.B/1.D receptors mediating cranial vasoconstriction relevant to migraine relief, and they have no antipsychotic, sedative, or hypnotic activity (unlike some older ergot-related or serotonergic agents) — all of these distinguishing features (selectivity, lack of antipsychotic/sedative/hypnotic activity, more favorable vascular profile) are True, comprehensive correct statements about triptans versus ergots.

5-H.T Receptor Agents — Clinical Correlations

- Naratriptan is used in migraine therapy specifically because it antagonizes 5-H.T.3 receptors — actually, this is False: triptans (including naratriptan) work by Agonizing 5-H.T.1.B/1.D receptors (causing cranial vasoconstriction and inhibiting trigeminal neuropeptide release), not by antagonizing 5-H.T.3 — a claim describing naratriptan's mechanism as "antagonizes 5-H.T.3 receptors" is incorrect framing of its true mechanism.

- 5-H.T.3 receptor antagonists (e.g., ondansetron) are used as antiemetics — True, this is the correct, well-established clinical use of the 5-H.T.3 antagonist drug class.

- Clozapine is notably an antipsychotic with 5-H.T.2.A antagonist activity (among its broad receptor profile) – used as an antipsychotic agent, consistent with standard atypical antipsychotic pharmacology.

9.7 Oral Antidiabetic Agents

Sulfonylureas

• Mechanism: stimulate pancreatic islet (beta) cells to secrete insulin (bind the Sur 1 subunit of the K-A.T.P channel, causing channel closure, membrane depolarization, and Ca superscript 2 plus -mediated insulin release) – the Correct mechanistic description among options.

• Second-generation sulfonylureas (glyburide, glipizide, glimepiride) compared to first-generation agents: show a Lesser propensity to cause hypoglycemia is actually generally considered False in some teaching frameworks (second-generation agents are actually more potent and can cause significant hypoglycemia; they are not necessarily "safer" in this regard) — but they do have shorter half-lives in some cases and are more potent (require lower mg doses) than first-generation agents — review the specific stem's framing carefully, as "False concerning their pharmacology" questions require matching to the specific listed option.

Thiazolidinediones (T.Z.D's, e. g., pioglitazone)

• Mechanism: activate P.P.A.R-gamma receptors, which diminish insulin resistance by increasing glucose uptake and metabolism in muscle and adipose tissue (improving peripheral insulin sensitivity) — this is the Correct description, distinguishing T.Z.D's from insulin secretagogues.

Alpha-Glucosidase Inhibitors (e. g., acarbose)

- Mechanism: competitively inhibit intestinal alpha-glucosidases, modulating (delaying) the postprandial digestion and absorption of starch and disaccharides – this slows carbohydrate absorption, blunting postprandial glucose spikes, Without stimulating insulin secretion directly.

Biguanides (Metformin)

- Mechanism: activates the enzyme A.M.P-activated protein kinase (A.M.P.K) – leads to decreased hepatic gluconeogenesis and improved peripheral glucose uptake – this is the Correct modern mechanistic understanding.

G.L.P-1 Receptor Agonists

• Mechanisms by which G.L.P-1 agonists reduce plasma glucose: slow gastric emptying, amplify glucose-dependent insulin release (glucose-dependent – reduces hypoglycemia risk compared to sulfonylureas), and suppress appetite – all True mechanisms. The one mechanism that is not how G.L.P-1 agonists work: they do not "activate glucagon release" – in fact, G.L.P-1 agonists suppress/inhibit glucagon release (glucagon is counter-regulatory, raises blood glucose) – "activate glucagon release" is the correct Except (false) answer among the listed mechanisms.

Enteroglucagons / Incretins

- Intestinal L-cells secrete enteroglucagons (which provoke a higher insulin response to a glucose load — the "incretin effect," explaining why oral glucose produces a greater insulin response than equivalent I.V glucose).

- Like glucagon, enteroglucagons are synthesized as a large precursor molecule (proglucagon).

• Glucagon-like peptides (G.L.P-1, G.L.P-2) are rapidly degraded by dipeptidyl peptidase-4 (D.P.P-4) – this is the physiologic basis for D.P.P-4 inhibitor drugs.

- Vildagliptin is an oral D.P.P-4 antagonist (inhibitor) that prolongs the action of endogenously released G.L.P-1 (by preventing its rapid degradation) – this is the Correct description; a claim that enteroglucagons "cannot be converted to glucagon" is generally considered the Wrong/false statement (there is some biochemical overlap/precursor relationship, and this blanket "cannot be converted" claim is typically the flagged incorrect statement in this stem).

9.8 Non-Opioid Analgesics — Acetaminophen

• Follows dose-dependent, first-order kinetics at therapeutic doses (though at toxic/overdose levels, kinetics can shift toward zero-order as metabolic pathways become saturated) — a blanket claim that acetaminophen "follows classic zero-order and first-order kinetics"

(implying zero-order at all doses) is an oversimplification/False as a general statement (it is primarily first-order at therapeutic doses).

- Should be used with caution in febrile children with suspected/possible viral illness in the context of Reye's syndrome — actually, this caution/association with Reye's syndrome is classically attributed to Aspirin (salicylates), not acetaminophen — a claim that acetaminophen "should be used with caution in febrile patients with Reye's syndrome" is generally the False/incorrect statement (acetaminophen is actually the Preferred antipyretic specifically to Avoid Reye's syndrome risk associated with aspirin).

- Toxicity is managed using N-acetylcysteine (N.A.C) – True, standard antidote for acetaminophen overdose (replenishes hepatic glutathione stores, allowing safe conjugation of the toxic metabolite napkee).

- N-acetylcysteine mechanism in acute paracetamol poisoning: acts as a free radical scavenger, replenishes hepatic glutathione which in turn binds/conjugates the toxic metabolite of paracetamol (napkee), and does not react directly with paracetamol itself "to form a nontoxic complex" (that describes a different, incorrect mechanism) — the correct comprehensive answer emphasizes glutathione replenishment and NAPQI conjugation/detoxification, along with antioxidant/free-radical-scavenging support, rather than direct chemical complexing with unmetabolized paracetamol. N.A.C does not "inhibit the generation of the toxic metabolite" per say (the toxic metabolite NAPQI is generated by C.Y.P.2.E.1 regardless; N.A.C's role is downstream detoxification via glutathione).

9.9 Antihistamines H.1 Receptor Antagonists) — Endocrine/Systemic Section Cross-Reference

- H.1-receptor blockade is known to suppress wakefulness (sedation) — a well-established class effect, especially with first-generation agents.

- First-generation antihistamines (e.g., chlorpheniramine) cross the blood-brain barrier and depress the reticular activating system, explaining their sedating properties.

• Second-generation antihistamines (e.g., loratadine) are non-sedating (poor C.N.S penetration due to P-glycoprotein efflux and lower lipophilicity), show more selective (peripheral H.1) activity, and have a Lower volume of distribution compared to first-generation agents (less tissue/C.N.S penetration) — all True, correct distinguishing pharmacologic features.

- BetaHistine has a strong affinity as an antagonist for H.3 receptors and a weak affinity as an agonist for H.1 receptors – used in vertigo/Meniere's disease management (a nuanced, specific pharmacology point).

- H.1 antagonists have antimuscarinic properties with usual side effects like drying of secretions; they have local anesthetic effects because of a sodium-channel-blocking effect (some first-generation H.1 blockers have membrane-stabilizing/local anesthetic properties at high concentrations, similar to some antiarrhythmics — an interesting cross-class pharmacologic point); they are used as antiemetics and anti-motion-sickness agents, acting in the C.N.S by blocking muscarinic and histamine receptors as well as having effects on the vestibular apparatus; and they are used in the management of acute dystonia (e.g., diphenhydramine for drug-induced extrapyramidal reactions, via central anticholinergic action) — this is a "classical use of 2nd-generation H.1 blockers in allergies, emesis, and motion sickness" would actually be considered False since it is specifically the first-generation (not second-generation) H.1 blockers that are classically used for emesis/motion sickness/dystonia (second-generation agents lack significant C.N.S penetration and are used almost exclusively for allergic conditions, not motion sickness or emesis).

- Clinical uses of H.1-receptor antagonists include urticaria and seasonal rhinitis (allergic rhinitis) – standard, well-established indications.

- Commonest adverse effect of (first-generation) antihistamines: sedation — True.

Section 10: Quick-Reference "Must-Know" High-Yield Contrasts

Table summary: Key distinguishing facts for commonly confused pharmaceutical concept pairs. For cardiac medications, Digoxin is characterized by renal clearance and a shorter half-life, while Digitoxin has hepatic clearance and a longer half-life of about seven days. Antiarrhythmics are differentiated by their block strength and effect on ECG intervals, with Class IA showing moderate block and increased QT/QRS, Class IB showing weak block, decreased QT, and selectivity for ischemic tissue, and Class IC showing strong block with marked QRS increase. For anticoagulants, Warfarin is oral with delayed onset and is contraindicated in pregnancy, whereas Heparin is parenteral with immediate onset and is safe in pregnancy. Acid reducers are split between H2RAs, which indirectly block histamine signals, and PPIs, which directly block the H plus K ATPase pump. Gout medications differ by mechanism, as Allopurinol decreases uric acid production and Probenecid increases its excretion. Lipid-lowering agents differ in target, with Statins lowering LDL and Fibrates lowering triglycerides and VLDL. Finally, potassium sparing diuretics include Spironolactone, an aldosterone receptor antagonist, and Triamterene or Amiloride, which are direct ENaC blockers. Diuretics are further split between Thiazides, which act on the DCT and favor hypercalcemia, and Loop diuretics, which act on the ascending LOH and provide potent diuresis.

Table summary: Key pharmacokinetic and distinguishing pharmacological facts for specific medications. Cimetidine is a potent CYP450 inhibitor with antiandrogenic effects leading to gynecomastia, whereas Ranitidine has minimal effects in these areas. Amiodarone's slow onset and long washout are explained by its 99.9 percent protein binding, a volume of distribution of approximately 66 liters per kilogram, and a half-life of about 25 days. In contrast, Adenosine has an ultra-rapid half-life of 1 to 10 seconds, requiring IV push administration, and is affected by theophylline, caffeine, and dipyridamole. One pair also notes a risk of ototoxicity, especially with ethacrynic acid, and a tendency to favor hypocalcemia through increased calcium excretion.

You have reached the end of the document.